Rank
|
PathwayID
|
Title
|
t+
|
t-
|
b+
|
b-
|
p-value
|
t-ratio
|
b-ratio
|
enrichment folds
|
1 | hsa04510 | Focal adhesion - Homo sapiens (human) | 75 | 951 | 197 | 25057 | 2.36e-42 | 0.07 | 0.01 | 9.4 |
2 | hsa04210 | Apoptosis - Homo sapiens (human) | 49 | 977 | 83 | 25171 | 6.68e-35 | 0.05 | 0.00 | 14.5 |
3 | hsa04010 | MAPK signaling pathway - Homo sapiens (human) | 73 | 953 | 259 | 24995 | 4.29e-34 | 0.07 | 0.01 | 6.9 |
4 | 109582 | Hemostasis | 62 | 964 | 172 | 25082 | 4.54e-34 | 0.06 | 0.01 | 8.9 |
5 | hsa05215 | Prostate cancer - Homo sapiens (human) | 49 | 977 | 93 | 25161 | 3.78e-33 | 0.05 | 0.00 | 13.0 |
6 | hsa04920 | Adipocytokine signaling pathway - Homo sapiens (human) | 45 | 981 | 72 | 25182 | 5.99e-33 | 0.04 | 0.00 | 15.4 |
7 | hsa04910 | Insulin signaling pathway - Homo sapiens (human) | 53 | 973 | 137 | 25117 | 1.68e-30 | 0.05 | 0.01 | 9.5 |
8 | hsa05212 | Pancreatic cancer - Homo sapiens (human) | 42 | 984 | 74 | 25180 | 1.42e-29 | 0.04 | 0.00 | 14.0 |
9 | 168256 | Signaling in Immune system | 72 | 954 | 312 | 24942 | 5.52e-29 | 0.07 | 0.01 | 5.7 |
10 | hsa05222 | Small cell lung cancer - Homo sapiens (human) | 43 | 983 | 87 | 25167 | 2.28e-28 | 0.04 | 0.00 | 12.2 |
11 | hsa05220 | Chronic myeloid leukemia - Homo sapiens (human) | 41 | 985 | 77 | 25177 | 4.46e-28 | 0.04 | 0.00 | 13.1 |
12 | hsa04670 | Leukocyte transendothelial migration - Homo sapiens (human) | 46 | 980 | 120 | 25134 | 1.69e-26 | 0.04 | 0.00 | 9.4 |
13 | hsa04620 | Toll-like receptor signaling pathway - Homo sapiens (human) | 43 | 983 | 102 | 25152 | 3.55e-26 | 0.04 | 0.00 | 10.4 |
14 | 166520 | Signalling by NGF | 46 | 980 | 125 | 25129 | 6.86e-26 | 0.04 | 0.00 | 9.1 |
15 | hsa04060 | Cytokine-cytokine receptor interaction - Homo sapiens (human) | 61 | 965 | 255 | 24999 | 2.02e-25 | 0.06 | 0.01 | 5.9 |
16 | hsa04810 | Regulation of actin cytoskeleton - Homo sapiens (human) | 56 | 970 | 214 | 25040 | 4.73e-25 | 0.05 | 0.01 | 6.4 |
17 | hsa04012 | ErbB signaling pathway - Homo sapiens (human) | 39 | 987 | 87 | 25167 | 1.24e-24 | 0.04 | 0.00 | 11.0 |
18 | 187037 | TRKA signalling from the plasma membrane | 36 | 990 | 75 | 25179 | 1.25e-23 | 0.04 | 0.00 | 11.8 |
19 | hsa05214 | Glioma - Homo sapiens (human) | 34 | 992 | 65 | 25189 | 2.56e-23 | 0.03 | 0.00 | 12.9 |
20 | hsa04664 | Fc epsilon RI signaling pathway - Homo sapiens (human) | 34 | 992 | 75 | 25179 | 9.06e-22 | 0.03 | 0.00 | 11.2 |
21 | hsa03320 | PPAR signaling pathway - Homo sapiens (human) | 32 | 994 | 69 | 25185 | 8.40e-21 | 0.03 | 0.00 | 11.4 |
22 | hsa05210 | Colorectal cancer - Homo sapiens (human) | 34 | 992 | 84 | 25170 | 1.57e-20 | 0.03 | 0.00 | 10.0 |
23 | hsa05221 | Acute myeloid leukemia - Homo sapiens (human) | 29 | 997 | 57 | 25197 | 7.79e-20 | 0.03 | 0.00 | 12.5 |
24 | hsa04630 | Jak-STAT signaling pathway - Homo sapiens (human) | 42 | 984 | 153 | 25101 | 9.33e-20 | 0.04 | 0.01 | 6.8 |
25 | hsa04660 | T cell receptor signaling pathway - Homo sapiens (human) | 34 | 992 | 92 | 25162 | 1.57e-19 | 0.03 | 0.00 | 9.1 |
26 | hsa05218 | Melanoma - Homo sapiens (human) | 31 | 995 | 72 | 25182 | 1.86e-19 | 0.03 | 0.00 | 10.6 |
27 | hsa04640 | Hematopoietic cell lineage - Homo sapiens (human) | 33 | 993 | 88 | 25166 | 3.75e-19 | 0.03 | 0.00 | 9.2 |
28 | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection - Homo sapiens (human) | 30 | 996 | 68 | 25186 | 4.15e-19 | 0.03 | 0.00 | 10.9 |
29 | hsa05211 | Renal cell carcinoma - Homo sapiens (human) | 30 | 996 | 69 | 25185 | 5.74e-19 | 0.03 | 0.00 | 10.7 |
30 | hsa04370 | VEGF signaling pathway - Homo sapiens (human) | 30 | 996 | 70 | 25184 | 7.90e-19 | 0.03 | 0.00 | 10.5 |
31 | hsa04650 | Natural killer cell mediated cytotoxicity - Homo sapiens (human) | 38 | 988 | 130 | 25124 | 8.91e-19 | 0.04 | 0.01 | 7.2 |
32 | hsa05223 | Non-small cell lung cancer - Homo sapiens (human) | 27 | 999 | 54 | 25200 | 2.06e-18 | 0.03 | 0.00 | 12.3 |
33 | hsa04912 | GnRH signaling pathway - Homo sapiens (human) | 33 | 993 | 97 | 25157 | 4.13e-18 | 0.03 | 0.00 | 8.4 |
34 | 109581 | Apoptosis | 29 | 997 | 69 | 25185 | 4.58e-18 | 0.03 | 0.00 | 10.3 |
35 | hsa04930 | Type II diabetes mellitus - Homo sapiens (human) | 24 | 1002 | 45 | 25209 | 5.21e-17 | 0.02 | 0.00 | 13.1 |
36 | hsa05219 | Bladder cancer - Homo sapiens (human) | 23 | 1003 | 41 | 25213 | 1.01e-16 | 0.02 | 0.00 | 13.8 |
37 | 198203 | PI3K/AKT signalling | 20 | 1006 | 31 | 25223 | 1.39e-15 | 0.02 | 0.00 | 15.9 |
38 | hsa04520 | Adherens junction - Homo sapiens (human) | 27 | 999 | 76 | 25178 | 1.89e-15 | 0.03 | 0.00 | 8.7 |
39 | 73923 | Lipid and lipoprotein metabolism | 36 | 990 | 156 | 25098 | 4.05e-15 | 0.04 | 0.01 | 5.7 |
40 | hsa04662 | B cell receptor signaling pathway - Homo sapiens (human) | 24 | 1002 | 63 | 25191 | 1.98e-14 | 0.02 | 0.00 | 9.4 |
41 | hsa00010 | Glycolysis / Gluconeogenesis - Homo sapiens (human) | 24 | 1002 | 64 | 25190 | 2.63e-14 | 0.02 | 0.00 | 9.2 |
42 | 71387 | Metabolism of carbohydrates | 28 | 998 | 95 | 25159 | 2.83e-14 | 0.03 | 0.00 | 7.3 |
43 | hsa05213 | Endometrial cancer - Homo sapiens (human) | 22 | 1004 | 52 | 25202 | 4.37e-14 | 0.02 | 0.00 | 10.4 |
44 | 163685 | Integration of energy metabolism | 24 | 1002 | 69 | 25185 | 1.01e-13 | 0.02 | 0.00 | 8.6 |
45 | 71406 | Pyruvate metabolism and TCA cycle | 17 | 1009 | 25 | 25229 | 1.01e-13 | 0.02 | 0.00 | 16.7 |
46 | hsa00020 | Citrate cycle (TCA cycle) - Homo sapiens (human) | 17 | 1009 | 27 | 25227 | 2.53e-13 | 0.02 | 0.00 | 15.5 |
47 | hsa04115 | p53 signaling pathway - Homo sapiens (human) | 23 | 1003 | 66 | 25188 | 3.18e-13 | 0.02 | 0.00 | 8.6 |
48 | hsa00590 | Arachidonic acid metabolism - Homo sapiens (human) | 21 | 1005 | 53 | 25201 | 4.58e-13 | 0.02 | 0.00 | 9.8 |
49 | 75178 | Formation of Platelet plug | 23 | 1003 | 69 | 25185 | 6.82e-13 | 0.02 | 0.00 | 8.2 |
50 | 202733 | Cell surface interactions at the vascular wall | 23 | 1003 | 70 | 25184 | 8.74e-13 | 0.02 | 0.00 | 8.1 |
51 | hsa04540 | Gap junction - Homo sapiens (human) | 26 | 1000 | 95 | 25159 | 9.87e-13 | 0.03 | 0.00 | 6.7 |
52 | hsa04080 | Neuroactive ligand-receptor interaction - Homo sapiens (human) | 45 | 981 | 302 | 24952 | 1.78e-12 | 0.04 | 0.01 | 3.7 |
53 | hsa04020 | Calcium signaling pathway - Homo sapiens (human) | 34 | 992 | 176 | 25078 | 1.90e-12 | 0.03 | 0.01 | 4.8 |
54 | hsa01510 | Neurodegenerative Diseases - Homo sapiens (human) | 18 | 1008 | 39 | 25215 | 2.82e-12 | 0.02 | 0.00 | 11.4 |
55 | 71291 | Metabolism of amino acids | 25 | 1001 | 92 | 25162 | 3.08e-12 | 0.02 | 0.00 | 6.7 |
56 | 74752 | Signaling by Insulin receptor | 18 | 1008 | 43 | 25211 | 1.03e-11 | 0.02 | 0.00 | 10.3 |
57 | hsa04150 | mTOR signaling pathway - Homo sapiens (human) | 18 | 1008 | 47 | 25207 | 3.37e-11 | 0.02 | 0.00 | 9.4 |
58 | hsa04916 | Melanogenesis - Homo sapiens (human) | 24 | 1002 | 101 | 25153 | 9.05e-11 | 0.02 | 0.00 | 5.8 |
59 | 140192 | Metabolism of xenobiotics | 23 | 1003 | 93 | 25161 | 1.13e-10 | 0.02 | 0.00 | 6.1 |
60 | 70326 | Glucose metabolism | 19 | 1007 | 60 | 25194 | 1.41e-10 | 0.02 | 0.00 | 7.8 |
61 | hsa00480 | Glutathione metabolism - Homo sapiens (human) | 16 | 1010 | 39 | 25215 | 1.84e-10 | 0.02 | 0.00 | 10.1 |
62 | hsa04110 | Cell cycle - Homo sapiens (human) | 25 | 1001 | 115 | 25139 | 1.88e-10 | 0.02 | 0.00 | 5.4 |
63 | 71403 | Citric acid cycle (TCA cycle) | 12 | 1014 | 16 | 25238 | 2.01e-10 | 0.01 | 0.00 | 18.5 |
64 | 71408 | Metabolism of small molecules | 21 | 1005 | 79 | 25175 | 2.35e-10 | 0.02 | 0.00 | 6.5 |
65 | 202403 | TCR signaling | 17 | 1009 | 47 | 25207 | 2.44e-10 | 0.02 | 0.00 | 8.9 |
66 | hsa04350 | TGF-beta signaling pathway - Homo sapiens (human) | 22 | 1004 | 89 | 25165 | 2.88e-10 | 0.02 | 0.00 | 6.1 |
67 | 77389 | IRS-related events | 15 | 1011 | 35 | 25219 | 4.21e-10 | 0.01 | 0.00 | 10.5 |
68 | hsa00620 | Pyruvate metabolism - Homo sapiens (human) | 16 | 1010 | 42 | 25212 | 4.44e-10 | 0.02 | 0.00 | 9.4 |
69 | 74751 | Insulin receptor signalling cascade | 15 | 1011 | 36 | 25218 | 5.76e-10 | 0.01 | 0.00 | 10.3 |
70 | hsa04730 | Long-term depression - Homo sapiens (human) | 20 | 1006 | 76 | 25178 | 7.30e-10 | 0.02 | 0.00 | 6.5 |
71 | 168898 | Toll Receptor Cascades | 16 | 1010 | 44 | 25210 | 7.72e-10 | 0.02 | 0.00 | 9.0 |
72 | hsa04940 | Type I diabetes mellitus - Homo sapiens (human) | 16 | 1010 | 44 | 25210 | 7.72e-10 | 0.02 | 0.00 | 9.0 |
73 | hsa04720 | Long-term potentiation - Homo sapiens (human) | 19 | 1007 | 68 | 25186 | 8.31e-10 | 0.02 | 0.00 | 6.9 |
74 | 202424 | Downstream TCR signaling | 15 | 1011 | 39 | 25215 | 1.40e-09 | 0.01 | 0.00 | 9.5 |
75 | hsa00330 | Arginine and proline metabolism - Homo sapiens (human) | 14 | 1012 | 35 | 25219 | 3.30e-09 | 0.01 | 0.00 | 9.8 |
76 | 168249 | Innate Immunity Signaling | 17 | 1009 | 59 | 25195 | 4.35e-09 | 0.02 | 0.00 | 7.1 |
77 | hsa00071 | Fatty acid metabolism - Homo sapiens (human) | 16 | 1010 | 51 | 25203 | 4.48e-09 | 0.02 | 0.00 | 7.7 |
78 | hsa00251 | Glutamate metabolism - Homo sapiens (human) | 13 | 1013 | 31 | 25223 | 7.65e-09 | 0.01 | 0.00 | 10.3 |
79 | 112399 | IRS-mediated signalling | 13 | 1013 | 32 | 25222 | 1.04e-08 | 0.01 | 0.00 | 10.0 |
80 | hsa04514 | Cell adhesion molecules (CAMs) - Homo sapiens (human) | 24 | 1002 | 133 | 25121 | 1.09e-08 | 0.02 | 0.01 | 4.4 |
81 | hsa04310 | Wnt signaling pathway - Homo sapiens (human) | 25 | 1001 | 147 | 25107 | 1.54e-08 | 0.02 | 0.01 | 4.2 |
82 | 168164 | Toll Like Receptor 3 (TLR3) Cascade | 11 | 1015 | 21 | 25233 | 1.85e-08 | 0.01 | 0.00 | 12.9 |
83 | 70268 | Cori Cycle (interconversion of glucose and lactate) | 13 | 1013 | 34 | 25220 | 1.86e-08 | 0.01 | 0.00 | 9.4 |
84 | 76005 | Response to elevated platelet cytosolic Ca++ | 15 | 1011 | 50 | 25204 | 2.24e-08 | 0.01 | 0.00 | 7.4 |
85 | hsa04512 | ECM-receptor interaction - Homo sapiens (human) | 19 | 1007 | 86 | 25168 | 2.25e-08 | 0.02 | 0.00 | 5.4 |
86 | hsa05010 | Alzheimer's disease - Homo sapiens (human) | 12 | 1014 | 28 | 25226 | 2.39e-08 | 0.01 | 0.00 | 10.5 |
87 | 168180 | TRAF6 Mediated Induction of the antiviral cytokine IFN-alpha/beta cascade | 10 | 1016 | 18 | 25236 | 5.44e-08 | 0.01 | 0.00 | 13.7 |
88 | 177929 | Signaling by EGFR | 14 | 1012 | 46 | 25208 | 5.68e-08 | 0.01 | 0.00 | 7.5 |
89 | 109606 | Intrinsic Pathway for Apoptosis | 12 | 1014 | 31 | 25223 | 5.89e-08 | 0.01 | 0.00 | 9.5 |
90 | hsa05216 | Thyroid cancer - Homo sapiens (human) | 12 | 1014 | 31 | 25223 | 5.89e-08 | 0.01 | 0.00 | 9.5 |
91 | hsa05040 | Huntington's disease - Homo sapiens (human) | 12 | 1014 | 31 | 25223 | 5.89e-08 | 0.01 | 0.00 | 9.5 |
92 | hsa00252 | Alanine and aspartate metabolism - Homo sapiens (human) | 12 | 1014 | 33 | 25221 | 1.03e-07 | 0.01 | 0.00 | 9.0 |
93 | 15869 | Nucleotide metabolism | 19 | 1007 | 99 | 25155 | 1.57e-07 | 0.02 | 0.00 | 4.7 |
94 | hsa05130 | Pathogenic Escherichia coli infection - EHEC - Homo sapiens (human) | 14 | 1012 | 51 | 25203 | 1.66e-07 | 0.01 | 0.00 | 6.8 |
95 | hsa05131 | Pathogenic Escherichia coli infection - EPEC - Homo sapiens (human) | 14 | 1012 | 51 | 25203 | 1.66e-07 | 0.01 | 0.00 | 6.8 |
96 | 163200 | Electron Transport Chain | 16 | 1010 | 70 | 25184 | 1.92e-07 | 0.02 | 0.00 | 5.6 |
97 | 73847 | Purine metabolism | 13 | 1013 | 44 | 25210 | 2.25e-07 | 0.01 | 0.00 | 7.3 |
98 | 70263 | Gluconeogenesis | 10 | 1016 | 22 | 25232 | 2.32e-07 | 0.01 | 0.00 | 11.2 |
99 | hsa00710 | Carbon fixation - Homo sapiens (human) | 10 | 1016 | 23 | 25231 | 3.21e-07 | 0.01 | 0.00 | 10.7 |
100 | hsa00650 | Butanoate metabolism - Homo sapiens (human) | 13 | 1013 | 46 | 25208 | 3.46e-07 | 0.01 | 0.00 | 7.0 |
101 | 114611 | Exocytosis of Alpha granule | 13 | 1013 | 46 | 25208 | 3.46e-07 | 0.01 | 0.00 | 7.0 |
102 | 114608 | Platelet degranulation | 13 | 1013 | 47 | 25207 | 4.26e-07 | 0.01 | 0.00 | 6.8 |
103 | 73887 | Death Receptor Signalling | 8 | 1018 | 12 | 25242 | 4.35e-07 | 0.01 | 0.00 | 16.4 |
104 | 109607 | Extrinsic Pathway for Apoptosis | 8 | 1018 | 12 | 25242 | 4.35e-07 | 0.01 | 0.00 | 16.4 |
105 | 140191 | Phase 1 functionalization | 10 | 1016 | 24 | 25230 | 4.39e-07 | 0.01 | 0.00 | 10.3 |
106 | hsa04950 | Maturity onset diabetes of the young - Homo sapiens (human) | 10 | 1016 | 25 | 25229 | 5.94e-07 | 0.01 | 0.00 | 9.8 |
107 | hsa05060 | Prion disease - Homo sapiens (human) | 8 | 1018 | 13 | 25241 | 6.79e-07 | 0.01 | 0.00 | 15.1 |
108 | 74231 | Purine biosynthesis | 10 | 1016 | 27 | 25227 | 1.05e-06 | 0.01 | 0.00 | 9.1 |
109 | hsa04530 | Tight junction - Homo sapiens (human) | 20 | 1006 | 126 | 25128 | 1.09e-06 | 0.02 | 0.00 | 3.9 |
110 | 187687 | Signalling to ERKs | 11 | 1015 | 35 | 25219 | 1.16e-06 | 0.01 | 0.00 | 7.7 |
111 | hsa00680 | Methane metabolism - Homo sapiens (human) | 7 | 1019 | 10 | 25244 | 1.87e-06 | 0.01 | 0.00 | 17.2 |
112 | hsa00260 | Glycine, serine and threonine metabolism - Homo sapiens (human) | 12 | 1014 | 46 | 25208 | 2.00e-06 | 0.01 | 0.00 | 6.4 |
113 | hsa00360 | Phenylalanine metabolism - Homo sapiens (human) | 10 | 1016 | 30 | 25224 | 2.30e-06 | 0.01 | 0.00 | 8.2 |
114 | hsa04610 | Complement and coagulation cascades - Homo sapiens (human) | 14 | 1012 | 69 | 25185 | 3.76e-06 | 0.01 | 0.00 | 5.0 |
115 | hsa00410 | beta-Alanine metabolism - Homo sapiens (human) | 9 | 1017 | 25 | 25229 | 4.42e-06 | 0.01 | 0.00 | 8.9 |
116 | 198323 | AKT phosphorylates targets in the cytosol | 7 | 1019 | 12 | 25242 | 4.52e-06 | 0.01 | 0.00 | 14.4 |
117 | 112412 | SOS-mediated signalling | 7 | 1019 | 12 | 25242 | 4.52e-06 | 0.01 | 0.00 | 14.4 |
118 | 111471 | Apoptotic factor-mediated response | 6 | 1020 | 7 | 25247 | 4.73e-06 | 0.01 | 0.00 | 21.1 |
119 | 167044 | Signalling to RAS | 9 | 1017 | 26 | 25228 | 5.74e-06 | 0.01 | 0.00 | 8.5 |
120 | 74226 | ATP formation | 8 | 1018 | 19 | 25235 | 6.01e-06 | 0.01 | 0.00 | 10.4 |
121 | hsa05030 | Amyotrophic lateral sclerosis (ALS) - Homo sapiens (human) | 8 | 1018 | 19 | 25235 | 6.01e-06 | 0.01 | 0.00 | 10.4 |
122 | hsa00280 | Valine, leucine and isoleucine degradation - Homo sapiens (human) | 11 | 1015 | 44 | 25210 | 7.53e-06 | 0.01 | 0.00 | 6.2 |
123 | 77388 | SHC-related events | 7 | 1019 | 14 | 25240 | 9.74e-06 | 0.01 | 0.00 | 12.3 |
124 | hsa00190 | Oxidative phosphorylation - Homo sapiens (human) | 17 | 1009 | 113 | 25141 | 1.28e-05 | 0.02 | 0.00 | 3.7 |
125 | 210990 | PECAM1 interactions | 6 | 1020 | 9 | 25245 | 1.29e-05 | 0.01 | 0.00 | 16.4 |
126 | 198693 | AKT phosphorylates targets in the nucleus | 6 | 1020 | 9 | 25245 | 1.29e-05 | 0.01 | 0.00 | 16.4 |
127 | hsa00930 | Caprolactam degradation - Homo sapiens (human) | 7 | 1019 | 15 | 25239 | 1.38e-05 | 0.01 | 0.00 | 11.5 |
128 | hsa05050 | Dentatorubropallidoluysian atrophy (DRPLA) - Homo sapiens (human) | 7 | 1019 | 15 | 25239 | 1.38e-05 | 0.01 | 0.00 | 11.5 |
129 | 109704 | PI3K Cascade | 8 | 1018 | 22 | 25232 | 1.43e-05 | 0.01 | 0.00 | 9.0 |
130 | hsa00561 | Glycerolipid metabolism - Homo sapiens (human) | 12 | 1014 | 59 | 25195 | 1.80e-05 | 0.01 | 0.00 | 5.0 |
131 | 70171 | Glycolysis | 8 | 1018 | 23 | 25231 | 1.86e-05 | 0.01 | 0.00 | 8.6 |
132 | 198725 | Nuclear Events (kinase and transcription factor activation) | 8 | 1018 | 23 | 25231 | 1.86e-05 | 0.01 | 0.00 | 8.6 |
133 | 170984 | ARMS-mediated activation | 7 | 1019 | 16 | 25238 | 1.92e-05 | 0.01 | 0.00 | 10.8 |
134 | 169893 | Prolonged ERK activation events | 7 | 1019 | 16 | 25238 | 1.92e-05 | 0.01 | 0.00 | 10.8 |
135 | 170968 | Frs2-mediated activation | 7 | 1019 | 16 | 25238 | 1.92e-05 | 0.01 | 0.00 | 10.8 |
136 | hsa00350 | Tyrosine metabolism - Homo sapiens (human) | 12 | 1014 | 60 | 25194 | 2.08e-05 | 0.01 | 0.00 | 4.9 |
137 | hsa00052 | Galactose metabolism - Homo sapiens (human) | 9 | 1017 | 33 | 25221 | 2.84e-05 | 0.01 | 0.00 | 6.7 |
138 | hsa00640 | Propanoate metabolism - Homo sapiens (human) | 9 | 1017 | 33 | 25221 | 2.84e-05 | 0.01 | 0.00 | 6.7 |
139 | hsa00720 | Reductive carboxylate cycle (CO2 fixation) - Homo sapiens (human) | 6 | 1020 | 11 | 25243 | 2.98e-05 | 0.01 | 0.00 | 13.4 |
140 | 77286 | mitochondrial fatty acid beta-oxidation of saturated fatty acids | 6 | 1020 | 11 | 25243 | 2.98e-05 | 0.01 | 0.00 | 13.4 |
141 | 198933 | Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | 12 | 1014 | 63 | 25191 | 3.18e-05 | 0.01 | 0.00 | 4.7 |
142 | 111459 | Activation of caspases through apoptosome-mediated cleavage | 5 | 1021 | 6 | 25248 | 3.41e-05 | 0.00 | 0.00 | 20.5 |
143 | 75157 | FasL/ CD95L signaling | 5 | 1021 | 6 | 25248 | 3.41e-05 | 0.00 | 0.00 | 20.5 |
144 | 111461 | Cytochrome c-mediated apoptotic response | 5 | 1021 | 6 | 25248 | 3.41e-05 | 0.00 | 0.00 | 20.5 |
145 | hsa00030 | Pentose phosphate pathway - Homo sapiens (human) | 8 | 1018 | 26 | 25228 | 3.86e-05 | 0.01 | 0.00 | 7.6 |
146 | 74749 | Signal attenuation | 6 | 1020 | 12 | 25242 | 4.33e-05 | 0.01 | 0.00 | 12.3 |
147 | hsa04360 | Axon guidance - Homo sapiens (human) | 17 | 1009 | 127 | 25127 | 4.89e-05 | 0.02 | 0.01 | 3.3 |
148 | hsa00940 | Phenylpropanoid biosynthesis - Homo sapiens (human) | 5 | 1021 | 7 | 25247 | 5.66e-05 | 0.00 | 0.00 | 17.6 |
149 | 140181 | Cytochrome p450 | 6 | 1020 | 13 | 25241 | 6.11e-05 | 0.01 | 0.00 | 11.4 |
150 | 75153 | Apoptotic execution phase | 7 | 1019 | 21 | 25233 | 7.80e-05 | 0.01 | 0.00 | 8.2 |
151 | 111465 | Cleavage of cellular proteins by active caspases | 7 | 1019 | 21 | 25233 | 7.80e-05 | 0.01 | 0.00 | 8.2 |
152 | 77289 | Mitochondrial Fatty Acid Beta-Oxidation | 6 | 1020 | 14 | 25240 | 8.45e-05 | 0.01 | 0.00 | 10.5 |
153 | hsa00310 | Lysine degradation - Homo sapiens (human) | 10 | 1016 | 49 | 25205 | 8.69e-05 | 0.01 | 0.00 | 5.0 |
154 | 140534 | Caspase-8 is formed from procaspase-8 | 5 | 1021 | 8 | 25246 | 8.90e-05 | 0.00 | 0.00 | 15.4 |
155 | 180292 | Gab1 signalosome | 5 | 1021 | 8 | 25246 | 8.90e-05 | 0.00 | 0.00 | 15.4 |
156 | 75205 | Dissolution of Fibrin Clot | 5 | 1021 | 8 | 25246 | 8.90e-05 | 0.00 | 0.00 | 15.4 |
157 | 204174 | Regulation of pyruvate dehydrogenase complex (PDC) | 5 | 1021 | 8 | 25246 | 8.90e-05 | 0.00 | 0.00 | 15.4 |
158 | 69416 | Activation of Pro-Caspase 8 | 5 | 1021 | 8 | 25246 | 8.90e-05 | 0.00 | 0.00 | 15.4 |
159 | hsa01430 | Cell Communication - Homo sapiens (human) | 17 | 1009 | 135 | 25119 | 9.67e-05 | 0.02 | 0.01 | 3.1 |
160 | 210993 | Tie2 Signaling | 6 | 1020 | 15 | 25239 | 1.14e-04 | 0.01 | 0.00 | 9.8 |
161 | 114509 | Platelet activation triggers | 6 | 1020 | 15 | 25239 | 1.14e-04 | 0.01 | 0.00 | 9.8 |
162 | 71064 | Lysine catabolism | 5 | 1021 | 9 | 25245 | 1.34e-04 | 0.00 | 0.00 | 13.7 |
163 | 109869 | MAP kinase cascade | 5 | 1021 | 9 | 25245 | 1.34e-04 | 0.00 | 0.00 | 13.7 |
164 | 190375 | FGFR2c ligand binding and activation | 6 | 1020 | 16 | 25238 | 1.52e-04 | 0.01 | 0.00 | 9.2 |
165 | hsa01040 | Polyunsaturated fatty acid biosynthesis - Homo sapiens (human) | 6 | 1020 | 16 | 25238 | 1.52e-04 | 0.01 | 0.00 | 9.2 |
166 | 166016 | Toll Like Receptor 4 (TLR4) Cascade | 7 | 1019 | 24 | 25230 | 1.57e-04 | 0.01 | 0.00 | 7.2 |
167 | hsa04612 | Antigen processing and presentation - Homo sapiens (human) | 13 | 1013 | 89 | 25165 | 1.70e-04 | 0.01 | 0.00 | 3.6 |
168 | hsa04614 | Renin-angiotensin system - Homo sapiens (human) | 6 | 1020 | 17 | 25237 | 1.99e-04 | 0.01 | 0.00 | 8.7 |
169 | 76002 | Platelet Activation | 6 | 1020 | 17 | 25237 | 1.99e-04 | 0.01 | 0.00 | 8.7 |
170 | 196854 | Metabolism of vitamins and cofactors | 10 | 1016 | 56 | 25198 | 2.28e-04 | 0.01 | 0.00 | 4.4 |
171 | hsa00564 | Glycerophospholipid metabolism - Homo sapiens (human) | 11 | 1015 | 68 | 25186 | 2.42e-04 | 0.01 | 0.00 | 4.0 |
172 | 111463 | SMAC binds to IAPs | 4 | 1022 | 5 | 25249 | 2.49e-04 | 0.00 | 0.00 | 19.7 |
173 | 199418 | Negative regulation of the PI3K/AKT network | 4 | 1022 | 5 | 25249 | 2.49e-04 | 0.00 | 0.00 | 19.7 |
174 | 111469 | SMAC-mediated apoptotic response | 4 | 1022 | 5 | 25249 | 2.49e-04 | 0.00 | 0.00 | 19.7 |
175 | 111464 | SMAC-mediated dissociation of IAP:caspase complexes | 4 | 1022 | 5 | 25249 | 2.49e-04 | 0.00 | 0.00 | 19.7 |
176 | 198753 | ERK/MAPK targets | 6 | 1020 | 18 | 25236 | 2.57e-04 | 0.01 | 0.00 | 8.2 |
177 | 112410 | SHC-mediated signalling | 5 | 1021 | 11 | 25243 | 2.74e-04 | 0.00 | 0.00 | 11.2 |
178 | 168927 | Viral dsRNA:TLR3:TRIF Complex Activates RIP1 | 5 | 1021 | 11 | 25243 | 2.74e-04 | 0.00 | 0.00 | 11.2 |
179 | 163359 | Glucagon signaling in metabolic regulation | 7 | 1019 | 27 | 25227 | 2.89e-04 | 0.01 | 0.00 | 6.4 |
180 | hsa04320 | Dorso-ventral axis formation - Homo sapiens (human) | 7 | 1019 | 28 | 25226 | 3.49e-04 | 0.01 | 0.00 | 6.2 |
181 | 190376 | FGFR ligand binding and activation | 7 | 1019 | 28 | 25226 | 3.49e-04 | 0.01 | 0.00 | 6.2 |
182 | 163210 | Formation of ATP by chemiosmotic coupling | 5 | 1021 | 12 | 25242 | 3.75e-04 | 0.00 | 0.00 | 10.3 |
183 | 71397 | Oxidative decarboxylation of pyruvate to acetyl CoA by pyruvate dehydrogenase | 4 | 1022 | 6 | 25248 | 4.02e-04 | 0.00 | 0.00 | 16.4 |
184 | 75158 | TRAIL signaling | 4 | 1022 | 6 | 25248 | 4.02e-04 | 0.00 | 0.00 | 16.4 |
185 | 75893 | TNF signaling | 4 | 1022 | 6 | 25248 | 4.02e-04 | 0.00 | 0.00 | 16.4 |
186 | 156580 | Phase II conjugation | 8 | 1018 | 40 | 25214 | 4.94e-04 | 0.01 | 0.00 | 4.9 |
187 | 140877 | Formation of Fibrin Clot (Clotting Cascade) | 7 | 1019 | 30 | 25224 | 5.00e-04 | 0.01 | 0.00 | 5.7 |
188 | 194138 | Signaling by VEGF | 5 | 1021 | 13 | 25241 | 5.03e-04 | 0.00 | 0.00 | 9.5 |
189 | hsa00630 | Glyoxylate and dicarboxylate metabolism - Homo sapiens (human) | 5 | 1021 | 13 | 25241 | 5.03e-04 | 0.00 | 0.00 | 9.5 |
190 | 69615 | G1/S DNA Damage Checkpoints | 5 | 1021 | 13 | 25241 | 5.03e-04 | 0.00 | 0.00 | 9.5 |
191 | 164378 | PKA activation in glucagon signalling | 5 | 1021 | 13 | 25241 | 5.03e-04 | 0.00 | 0.00 | 9.5 |
192 | 190241 | FGFR2 ligand binding and activation | 6 | 1020 | 21 | 25233 | 5.10e-04 | 0.01 | 0.00 | 7.0 |
193 | 190236 | Signaling by FGFR | 7 | 1019 | 31 | 25223 | 5.92e-04 | 0.01 | 0.00 | 5.6 |
194 | 196836 | Vitamin C (ascorbate) metabolism | 4 | 1022 | 7 | 25247 | 6.12e-04 | 0.00 | 0.00 | 14.1 |
195 | 74713 | IRS activation | 4 | 1022 | 7 | 25247 | 6.12e-04 | 0.00 | 0.00 | 14.1 |
196 | 196849 | Metabolism of water-soluble vitamins and cofactors | 8 | 1018 | 42 | 25212 | 6.57e-04 | 0.01 | 0.00 | 4.7 |
197 | 187706 | Signalling to p38 via RIT and RIN | 5 | 1021 | 14 | 25240 | 6.61e-04 | 0.00 | 0.00 | 8.8 |
198 | hsa04070 | Phosphatidylinositol signaling system - Homo sapiens (human) | 11 | 1015 | 78 | 25176 | 6.88e-04 | 0.01 | 0.00 | 3.5 |
199 | 190239 | FGFR3 ligand binding and activation | 5 | 1021 | 15 | 25239 | 8.53e-04 | 0.00 | 0.00 | 8.2 |
200 | 190372 | FGFR3c ligand binding and activation | 5 | 1021 | 15 | 25239 | 8.53e-04 | 0.00 | 0.00 | 8.2 |
201 | 114696 | Thrombin-activated activation cascade | 4 | 1022 | 8 | 25246 | 8.89e-04 | 0.00 | 0.00 | 12.3 |
202 | 114665 | G-protein cascades | 4 | 1022 | 8 | 25246 | 8.89e-04 | 0.00 | 0.00 | 12.3 |
203 | 111458 | Formation of apoptosome | 3 | 1023 | 3 | 25251 | 1.09e-03 | 0.00 | 0.00 | 24.6 |
204 | 167826 | The fatty acid cycling model | 3 | 1023 | 3 | 25251 | 1.09e-03 | 0.00 | 0.00 | 24.6 |
205 | 166187 | Mitochondrial Uncoupling Proteins | 3 | 1023 | 3 | 25251 | 1.09e-03 | 0.00 | 0.00 | 24.6 |
206 | 70102 | Phosphoenolpyruvate and ADP react to form pyruvate and ATP | 3 | 1023 | 3 | 25251 | 1.09e-03 | 0.00 | 0.00 | 24.6 |
207 | 167827 | The proton buffering model | 3 | 1023 | 3 | 25251 | 1.09e-03 | 0.00 | 0.00 | 24.6 |
208 | hsa00380 | Tryptophan metabolism - Homo sapiens (human) | 11 | 1015 | 84 | 25170 | 1.19e-03 | 0.01 | 0.00 | 3.2 |
209 | 69580 | p53-Dependent G1/S DNA damage checkpoint | 4 | 1022 | 9 | 25245 | 1.25e-03 | 0.00 | 0.00 | 10.9 |
210 | hsa00430 | Taurine and hypotaurine metabolism - Homo sapiens (human) | 4 | 1022 | 9 | 25245 | 1.25e-03 | 0.00 | 0.00 | 10.9 |
211 | 69563 | p53-Dependent G1 DNA Damage Response | 4 | 1022 | 9 | 25245 | 1.25e-03 | 0.00 | 0.00 | 10.9 |
212 | 69236 | G1 Phase | 5 | 1021 | 17 | 25237 | 1.36e-03 | 0.00 | 0.00 | 7.2 |
213 | 69231 | Cyclin D associated events in G1 | 5 | 1021 | 17 | 25237 | 1.36e-03 | 0.00 | 0.00 | 7.2 |
214 | 190322 | FGFR4 ligand binding and activation | 5 | 1021 | 17 | 25237 | 1.36e-03 | 0.00 | 0.00 | 7.2 |
215 | 69242 | S Phase | 9 | 1017 | 60 | 25194 | 1.41e-03 | 0.01 | 0.00 | 3.7 |
216 | hsa04130 | SNARE interactions in vesicular transport - Homo sapiens (human) | 7 | 1019 | 38 | 25216 | 1.68e-03 | 0.01 | 0.00 | 4.5 |
217 | 164385 | G(s)-alpha mediated events in glucagon signalling | 5 | 1021 | 18 | 25236 | 1.68e-03 | 0.00 | 0.00 | 6.8 |
218 | 77352 | Beta oxidation of butanoyl-CoA to acetyl-CoA | 3 | 1023 | 4 | 25250 | 1.85e-03 | 0.00 | 0.00 | 18.5 |
219 | hsa00471 | D-Glutamine and D-glutamate metabolism - Homo sapiens (human) | 3 | 1023 | 4 | 25250 | 1.85e-03 | 0.00 | 0.00 | 18.5 |
220 | 163680 | AMPK inhibits chREBP transcriptional activation activity | 3 | 1023 | 4 | 25250 | 1.85e-03 | 0.00 | 0.00 | 18.5 |
221 | 75894 | Synthesis of lysophosphatidic acid from glycerol-3-phosphate | 3 | 1023 | 4 | 25250 | 1.85e-03 | 0.00 | 0.00 | 18.5 |
222 | 202427 | Phosphorylation of CD3 and TCR zeta chains | 5 | 1021 | 19 | 25235 | 2.05e-03 | 0.00 | 0.00 | 6.5 |
223 | 170834 | Signaling by TGF beta | 5 | 1021 | 19 | 25235 | 2.05e-03 | 0.00 | 0.00 | 6.5 |
224 | hsa00903 | Limonene and pinene degradation - Homo sapiens (human) | 6 | 1020 | 29 | 25225 | 2.15e-03 | 0.01 | 0.00 | 5.1 |
225 | 140875 | Common Pathway | 4 | 1022 | 11 | 25243 | 2.23e-03 | 0.00 | 0.00 | 9.0 |
226 | 75892 | Platelet Adhesion to exposed collagen | 4 | 1022 | 11 | 25243 | 2.23e-03 | 0.00 | 0.00 | 9.0 |
227 | 166054 | Activated TLR4 signalling | 5 | 1021 | 20 | 25234 | 2.49e-03 | 0.00 | 0.00 | 6.2 |
228 | hsa00220 | Urea cycle and metabolism of amino groups - Homo sapiens (human) | 6 | 1020 | 30 | 25224 | 2.49e-03 | 0.01 | 0.00 | 4.9 |
229 | hsa00790 | Folate biosynthesis - Homo sapiens (human) | 7 | 1019 | 42 | 25212 | 2.78e-03 | 0.01 | 0.00 | 4.1 |
230 | 75815 | Ubiquitin-dependent degradation of Cyclin D | 3 | 1023 | 5 | 25249 | 2.87e-03 | 0.00 | 0.00 | 14.8 |
231 | 194306 | Neurophilin interactions with VEGF and VEGFR | 3 | 1023 | 5 | 25249 | 2.87e-03 | 0.00 | 0.00 | 14.8 |
232 | 69229 | Ubiquitin-dependent degradation of Cyclin D1 | 3 | 1023 | 5 | 25249 | 2.87e-03 | 0.00 | 0.00 | 14.8 |
233 | 70614 | Aspartate, asparagine, glutamate, and glutamine metabolism | 3 | 1023 | 5 | 25249 | 2.87e-03 | 0.00 | 0.00 | 14.8 |
234 | 114666 | G alpha Q cascade | 3 | 1023 | 5 | 25249 | 2.87e-03 | 0.00 | 0.00 | 14.8 |
235 | 140182 | P450 Epoxidations | 3 | 1023 | 5 | 25249 | 2.87e-03 | 0.00 | 0.00 | 14.8 |
236 | 187577 | SCF(Skp2)-mediated degradation of p27/p21 | 3 | 1023 | 5 | 25249 | 2.87e-03 | 0.00 | 0.00 | 14.8 |
237 | 202433 | Generation of second messenger molecules | 5 | 1021 | 21 | 25233 | 2.98e-03 | 0.00 | 0.00 | 5.9 |
238 | 69206 | G1/S Transition | 8 | 1018 | 55 | 25199 | 3.03e-03 | 0.01 | 0.00 | 3.6 |
239 | hsa00051 | Fructose and mannose metabolism - Homo sapiens (human) | 7 | 1019 | 43 | 25211 | 3.12e-03 | 0.01 | 0.00 | 4.0 |
240 | hsa00980 | Metabolism of xenobiotics by cytochrome P450 - Homo sapiens (human) | 9 | 1017 | 70 | 25184 | 3.62e-03 | 0.01 | 0.00 | 3.2 |
241 | 75109 | Triacylglyceride Biosynthesis | 4 | 1022 | 13 | 25241 | 3.66e-03 | 0.00 | 0.00 | 7.6 |
242 | 114592 | Collagen adhesion via alpha 2 beta 1 glycoprotein | 3 | 1023 | 6 | 25248 | 4.18e-03 | 0.00 | 0.00 | 12.3 |
243 | 77350 | Beta oxidation of hexanoyl-CoA to butanoyl-CoA | 3 | 1023 | 6 | 25248 | 4.18e-03 | 0.00 | 0.00 | 12.3 |
244 | 179812 | Grb2 events in EGFR signaling | 3 | 1023 | 6 | 25248 | 4.18e-03 | 0.00 | 0.00 | 12.3 |
245 | 77348 | Beta oxidation of octanoyl-CoA to hexanoyl-CoA | 3 | 1023 | 6 | 25248 | 4.18e-03 | 0.00 | 0.00 | 12.3 |
246 | 77346 | Beta oxidation of decanoyl-CoA to octanoyl-CoA-CoA | 3 | 1023 | 6 | 25248 | 4.18e-03 | 0.00 | 0.00 | 12.3 |
247 | 190373 | FGFR1c ligand binding and activation | 4 | 1022 | 14 | 25240 | 4.56e-03 | 0.00 | 0.00 | 7.0 |
248 | hsa00591 | Linoleic acid metabolism - Homo sapiens (human) | 6 | 1020 | 35 | 25219 | 4.88e-03 | 0.01 | 0.00 | 4.2 |
249 | hsa00592 | alpha-Linolenic acid metabolism - Homo sapiens (human) | 4 | 1022 | 15 | 25239 | 5.60e-03 | 0.00 | 0.00 | 6.6 |
250 | 171007 | p38MAPK events | 4 | 1022 | 15 | 25239 | 5.60e-03 | 0.00 | 0.00 | 6.6 |
251 | 202670 | ERKs are inactivated | 3 | 1023 | 7 | 25247 | 5.79e-03 | 0.00 | 0.00 | 10.5 |
252 | 195399 | VEGF binds to VEGFR leading to receptor dimerization | 3 | 1023 | 7 | 25247 | 5.79e-03 | 0.00 | 0.00 | 10.5 |
253 | 71288 | Creatine metabolism | 3 | 1023 | 7 | 25247 | 5.79e-03 | 0.00 | 0.00 | 10.5 |
254 | 112407 | RAF phosphorylates MEK | 3 | 1023 | 7 | 25247 | 5.79e-03 | 0.00 | 0.00 | 10.5 |
255 | 110049 | MEK activation | 3 | 1023 | 7 | 25247 | 5.79e-03 | 0.00 | 0.00 | 10.5 |
256 | 77310 | Beta oxidation of lauroyl-CoA to decanoyl-CoA-CoA | 3 | 1023 | 7 | 25247 | 5.79e-03 | 0.00 | 0.00 | 10.5 |
257 | 109312 | Hydrolysis of nucleoside 5'-monophosphates to nucleosides plus orthophosphate | 3 | 1023 | 7 | 25247 | 5.79e-03 | 0.00 | 0.00 | 10.5 |
258 | 180336 | Shc events in EGFR signaling | 3 | 1023 | 7 | 25247 | 5.79e-03 | 0.00 | 0.00 | 10.5 |
259 | 71182 | Phenylalanine and tyrosine catabolism | 3 | 1023 | 7 | 25247 | 5.79e-03 | 0.00 | 0.00 | 10.5 |
260 | 70153 | Glucose uptake | 3 | 1023 | 7 | 25247 | 5.79e-03 | 0.00 | 0.00 | 10.5 |
261 | hsa00562 | Inositol phosphate metabolism - Homo sapiens (human) | 7 | 1019 | 50 | 25204 | 6.54e-03 | 0.01 | 0.00 | 3.4 |
262 | 168176 | Toll Like Receptor 5 (TLR5) Cascade | 4 | 1022 | 16 | 25238 | 6.79e-03 | 0.00 | 0.00 | 6.2 |
263 | 202430 | Translocation of ZAP-70 to Immunological synapse | 4 | 1022 | 16 | 25238 | 6.79e-03 | 0.00 | 0.00 | 6.2 |
264 | 166058 | MyD88 cascade | 4 | 1022 | 16 | 25238 | 6.79e-03 | 0.00 | 0.00 | 6.2 |
265 | 168142 | Toll Like Receptor 10 (TLR10) Cascade | 4 | 1022 | 16 | 25238 | 6.79e-03 | 0.00 | 0.00 | 6.2 |
266 | 168188 | Toll Like Receptor TLR6:TLR2 Cascade | 4 | 1022 | 16 | 25238 | 6.79e-03 | 0.00 | 0.00 | 6.2 |
267 | 181438 | Toll Like Receptor 2 Cascade | 4 | 1022 | 16 | 25238 | 6.79e-03 | 0.00 | 0.00 | 6.2 |
268 | 168179 | Toll Like Receptor TLR1:TLR2 Cascade | 4 | 1022 | 16 | 25238 | 6.79e-03 | 0.00 | 0.00 | 6.2 |
269 | 168181 | Toll Like Receptor 7/8 (TLR7/8) Cascade | 4 | 1022 | 16 | 25238 | 6.79e-03 | 0.00 | 0.00 | 6.2 |
270 | 69656 | Cyclin A:Cdk2-associated events at S phase entry | 4 | 1022 | 16 | 25238 | 6.79e-03 | 0.00 | 0.00 | 6.2 |
271 | 69239 | Synthesis of DNA | 7 | 1019 | 51 | 25203 | 7.19e-03 | 0.01 | 0.00 | 3.4 |
272 | 69052 | Switching of origins to a post-replicative state | 5 | 1021 | 27 | 25227 | 7.53e-03 | 0.00 | 0.00 | 4.6 |
273 | 68949 | Orc1 removal from chromatin | 5 | 1021 | 27 | 25227 | 7.53e-03 | 0.00 | 0.00 | 4.6 |
274 | 173107 | Binding and entry of HIV virion | 3 | 1023 | 8 | 25246 | 7.74e-03 | 0.00 | 0.00 | 9.2 |
275 | 156581 | Methylation | 3 | 1023 | 8 | 25246 | 7.74e-03 | 0.00 | 0.00 | 9.2 |
276 | 71384 | Ethanol catabolism | 3 | 1023 | 8 | 25246 | 7.74e-03 | 0.00 | 0.00 | 9.2 |
277 | 200409 | Activated AMPK stimulates fatty-acid oxidation in muscle | 3 | 1023 | 8 | 25246 | 7.74e-03 | 0.00 | 0.00 | 9.2 |
278 | 202131 | Metabolism of nitric oxide | 4 | 1022 | 17 | 25237 | 8.13e-03 | 0.00 | 0.00 | 5.8 |
279 | 156590 | Glutathione conjugation | 4 | 1022 | 17 | 25237 | 8.13e-03 | 0.00 | 0.00 | 5.8 |
280 | 69304 | Regulation of DNA replication | 5 | 1021 | 28 | 25226 | 8.59e-03 | 0.00 | 0.00 | 4.4 |
281 | 69300 | Removal of licensing factors from origins | 5 | 1021 | 28 | 25226 | 8.59e-03 | 0.00 | 0.00 | 4.4 |
282 | 170822 | Negative Regulation of Glucokinase by Glucokinase Regulatory Protein | 2 | 1024 | 2 | 25252 | 8.67e-03 | 0.00 | 0.00 | 24.6 |
283 | 111807 | Reduction of nuclear ribonucleoside 5'-diphosphates to deoxyribonucleoside 5'-diphosphates by ribonucleotide reductase and thioredoxin | 2 | 1024 | 2 | 25252 | 8.67e-03 | 0.00 | 0.00 | 24.6 |
284 | 198765 | Signalling to ERK5 | 2 | 1024 | 2 | 25252 | 8.67e-03 | 0.00 | 0.00 | 24.6 |
285 | 111457 | Release of apoptotic factors from the mitochondria | 2 | 1024 | 2 | 25252 | 8.67e-03 | 0.00 | 0.00 | 24.6 |
286 | 111804 | Reduction of nuclear ribonucleoside 5'-diphosphates to deoxyribonucleoside 5'-diphosphates (thioredoxin) | 2 | 1024 | 2 | 25252 | 8.67e-03 | 0.00 | 0.00 | 24.6 |
287 | 212718 | EGFR interacts with phospholipase C-gamma | 2 | 1024 | 2 | 25252 | 8.67e-03 | 0.00 | 0.00 | 24.6 |
288 | 112409 | ERK activation | 2 | 1024 | 2 | 25252 | 8.67e-03 | 0.00 | 0.00 | 24.6 |
289 | hsa00860 | Porphyrin and chlorophyll metabolism - Homo sapiens (human) | 6 | 1020 | 41 | 25213 | 9.56e-03 | 0.01 | 0.00 | 3.6 |
290 | hsa00760 | Nicotinate and nicotinamide metabolism - Homo sapiens (human) | 6 | 1020 | 41 | 25213 | 9.56e-03 | 0.01 | 0.00 | 3.6 |
291 | 69202 | Cyclin E associated events during G1/S transition | 4 | 1022 | 18 | 25236 | 9.63e-03 | 0.00 | 0.00 | 5.5 |
292 | hsa00271 | Methionine metabolism - Homo sapiens (human) | 4 | 1022 | 18 | 25236 | 9.63e-03 | 0.00 | 0.00 | 5.5 |
293 | 140837 | Intrinsic Pathway | 4 | 1022 | 18 | 25236 | 9.63e-03 | 0.00 | 0.00 | 5.5 |
294 | 168138 | Toll Like Receptor 9 (TLR9) Cascade | 4 | 1022 | 18 | 25236 | 9.63e-03 | 0.00 | 0.00 | 5.5 |
295 | 194313 | VEGF ligand-receptor interactions | 3 | 1023 | 9 | 25245 | 1.00e-02 | 0.00 | 0.00 | 8.2 |
296 | 190371 | FGFR3b ligand binding and activation | 3 | 1023 | 9 | 25245 | 1.00e-02 | 0.00 | 0.00 | 8.2 |
297 | 159763 | Transport of gamma-carboxylated protein precursors from the endoplasmic reticulum to the Golgi apparatus | 3 | 1023 | 9 | 25245 | 1.00e-02 | 0.00 | 0.00 | 8.2 |
298 | 75877 | Conversion of Fatty Acyl-CoA to Phosphatidic Acid | 3 | 1023 | 9 | 25245 | 1.00e-02 | 0.00 | 0.00 | 8.2 |
299 | hsa00521 | Streptomycin biosynthesis - Homo sapiens (human) | 3 | 1023 | 9 | 25245 | 1.00e-02 | 0.00 | 0.00 | 8.2 |
300 | hsa05217 | Basal cell carcinoma - Homo sapiens (human) | 7 | 1019 | 55 | 25199 | 1.03e-02 | 0.01 | 0.00 | 3.1 |
301 | hsa00230 | Purine metabolism - Homo sapiens (human) | 13 | 1013 | 147 | 25107 | 1.18e-02 | 0.01 | 0.01 | 2.2 |
302 | hsa04120 | Ubiquitin mediated proteolysis - Homo sapiens (human) | 12 | 1014 | 128 | 25126 | 1.26e-02 | 0.01 | 0.01 | 2.3 |
303 | 174800 | Chylomicron-mediated lipid transport | 3 | 1023 | 10 | 25244 | 1.26e-02 | 0.00 | 0.00 | 7.4 |
304 | 199920 | CREB phosphorylation | 3 | 1023 | 10 | 25244 | 1.26e-02 | 0.00 | 0.00 | 7.4 |
305 | 174824 | Lipoprotein metabolism | 3 | 1023 | 10 | 25244 | 1.26e-02 | 0.00 | 0.00 | 7.4 |
306 | hsa00062 | Fatty acid elongation in mitochondria - Homo sapiens (human) | 3 | 1023 | 10 | 25244 | 1.26e-02 | 0.00 | 0.00 | 7.4 |
307 | 163560 | Hormone-sensitive lipase (HSL)-mediated triacylglycerol hydrolysis | 3 | 1023 | 10 | 25244 | 1.26e-02 | 0.00 | 0.00 | 7.4 |
308 | hsa02010 | ABC transporters - General - Homo sapiens (human) | 6 | 1020 | 44 | 25210 | 1.28e-02 | 0.01 | 0.00 | 3.4 |
309 | 190242 | FGFR1 ligand binding and activation | 4 | 1022 | 20 | 25234 | 1.32e-02 | 0.00 | 0.00 | 4.9 |
310 | 174403 | Glutathione synthesis | 2 | 1024 | 3 | 25251 | 1.41e-02 | 0.00 | 0.00 | 16.4 |
311 | 111752 | Reduction of cytosolic ribonucleoside 5'-diphosphates to deoxyribonucleoside 5'-diphosphates by ribonucleotide reductase and thioredoxin | 2 | 1024 | 3 | 25251 | 1.41e-02 | 0.00 | 0.00 | 16.4 |
312 | 180897 | Vpr-mediated induction of apoptosis by mitochondrial outer membrane permeabilization | 2 | 1024 | 3 | 25251 | 1.41e-02 | 0.00 | 0.00 | 16.4 |
313 | 114516 | Disinhibition of SNARE formation | 2 | 1024 | 3 | 25251 | 1.41e-02 | 0.00 | 0.00 | 16.4 |
314 | 140187 | P450 Prostaglandin isomerizations | 2 | 1024 | 3 | 25251 | 1.41e-02 | 0.00 | 0.00 | 16.4 |
315 | 71037 | Oxidative decarboxylation of alpha-ketoadipate to glutaryl CoA by alpha-ketoglutarate dehydrogenase | 2 | 1024 | 3 | 25251 | 1.41e-02 | 0.00 | 0.00 | 16.4 |
316 | 77378 | Formation of Cytosolic Glycerol-3-phosphate | 2 | 1024 | 3 | 25251 | 1.41e-02 | 0.00 | 0.00 | 16.4 |
317 | 75944 | Transcription from mitochondrial promoters | 2 | 1024 | 3 | 25251 | 1.41e-02 | 0.00 | 0.00 | 16.4 |
318 | 165158 | Activation of PKB | 2 | 1024 | 3 | 25251 | 1.41e-02 | 0.00 | 0.00 | 16.4 |
319 | 163282 | Mitochondrial transcription initiation | 2 | 1024 | 3 | 25251 | 1.41e-02 | 0.00 | 0.00 | 16.4 |
320 | 77387 | Insulin receptor recycling | 2 | 1024 | 3 | 25251 | 1.41e-02 | 0.00 | 0.00 | 16.4 |
321 | 71401 | Oxidative decarboxylation of alpha-ketoglutarate to succinyl CoA by alpha-ketoglutarate dehydrogenase | 2 | 1024 | 3 | 25251 | 1.41e-02 | 0.00 | 0.00 | 16.4 |
322 | 75852 | Formation of Malonyl-ACP on the other FAS monomer | 2 | 1024 | 3 | 25251 | 1.41e-02 | 0.00 | 0.00 | 16.4 |
323 | 111751 | Reduction of cytosolic ribonucleoside 5'-diphosphates to deoxyribonucleoside 5'-diphosphates (thioredoxin) | 2 | 1024 | 3 | 25251 | 1.41e-02 | 0.00 | 0.00 | 16.4 |
324 | hsa00960 | Alkaloid biosynthesis II - Homo sapiens (human) | 4 | 1022 | 21 | 25233 | 1.52e-02 | 0.00 | 0.00 | 4.7 |
325 | 159782 | Removal of aminoterminal propeptides from gamma-carboxylated proteins | 3 | 1023 | 11 | 25243 | 1.56e-02 | 0.00 | 0.00 | 6.7 |
326 | 159740 | Gamma-carboxylation of protein precursors | 3 | 1023 | 11 | 25243 | 1.56e-02 | 0.00 | 0.00 | 6.7 |
327 | 111748 | Synthesis of deoxyribonucleoside 5'-diphosphates from ribonucleoside 5'-diphosphates | 2 | 1024 | 4 | 25250 | 2.06e-02 | 0.00 | 0.00 | 12.3 |
328 | 74744 | SHC activation | 2 | 1024 | 4 | 25250 | 2.06e-02 | 0.00 | 0.00 | 12.3 |
329 | 168782 | Proteolytic cleavage of SNARE complex proteins | 2 | 1024 | 4 | 25250 | 2.06e-02 | 0.00 | 0.00 | 12.3 |
330 | 166020 | LPS transferred from LBP carrier to CD14 | 2 | 1024 | 4 | 25250 | 2.06e-02 | 0.00 | 0.00 | 12.3 |
331 | 75107 | Butyryl-ACP biosynthesis | 2 | 1024 | 4 | 25250 | 2.06e-02 | 0.00 | 0.00 | 12.3 |
332 | 69017 | CDK-mediated phosphorylation and removal of Cdc6 | 2 | 1024 | 4 | 25250 | 2.06e-02 | 0.00 | 0.00 | 12.3 |
333 | 110029 | RAF activation | 2 | 1024 | 4 | 25250 | 2.06e-02 | 0.00 | 0.00 | 12.3 |
334 | 139943 | PLC-mediated hydrolysis | 2 | 1024 | 4 | 25250 | 2.06e-02 | 0.00 | 0.00 | 12.3 |
335 | 76000 | Assembly of the RAD51-ssDNA nucleoprotein complex | 2 | 1024 | 4 | 25250 | 2.06e-02 | 0.00 | 0.00 | 12.3 |
336 | 77108 | Utilization of Ketone Bodies | 2 | 1024 | 4 | 25250 | 2.06e-02 | 0.00 | 0.00 | 12.3 |
337 | 76420 | Simple hydroxylation | 2 | 1024 | 4 | 25250 | 2.06e-02 | 0.00 | 0.00 | 12.3 |
338 | 162594 | Early Phase of HIV Life Cycle | 3 | 1023 | 13 | 25241 | 2.27e-02 | 0.00 | 0.00 | 5.7 |
339 | 159854 | Gamma-carboxylation, transport, and amino-terminal cleavage of proteins | 3 | 1023 | 13 | 25241 | 2.27e-02 | 0.00 | 0.00 | 5.7 |
340 | 69278 | Cell Cycle, Mitotic | 14 | 1012 | 178 | 25076 | 2.30e-02 | 0.01 | 0.01 | 1.9 |
341 | 69002 | DNA Replication Pre-Initiation | 5 | 1021 | 37 | 25217 | 2.31e-02 | 0.00 | 0.00 | 3.3 |
342 | 70221 | Glycogen breakdown (glycogenolysis) | 3 | 1023 | 14 | 25240 | 2.68e-02 | 0.00 | 0.00 | 5.3 |
343 | hsa00600 | Sphingolipid metabolism - Homo sapiens (human) | 5 | 1021 | 39 | 25215 | 2.77e-02 | 0.00 | 0.00 | 3.2 |
344 | 76010 | Homologous DNA pairing and strand exchange | 2 | 1024 | 5 | 25249 | 2.81e-02 | 0.00 | 0.00 | 9.8 |
345 | 70114 | Glucose + ATP => glucose-6-phosphate + ADP | 2 | 1024 | 5 | 25249 | 2.81e-02 | 0.00 | 0.00 | 9.8 |
346 | 140186 | P450 Hydroxylations | 2 | 1024 | 5 | 25249 | 2.81e-02 | 0.00 | 0.00 | 9.8 |
347 | 74219 | dGTP formation | 2 | 1024 | 5 | 25249 | 2.81e-02 | 0.00 | 0.00 | 9.8 |
348 | hsa00950 | Alkaloid biosynthesis I - Homo sapiens (human) | 2 | 1024 | 5 | 25249 | 2.81e-02 | 0.00 | 0.00 | 9.8 |
349 | 74257 | Xanthine formation | 2 | 1024 | 5 | 25249 | 2.81e-02 | 0.00 | 0.00 | 9.8 |
350 | 114508 | Phospholipase-mediated signalling | 2 | 1024 | 5 | 25249 | 2.81e-02 | 0.00 | 0.00 | 9.8 |
351 | hsa00281 | Geraniol degradation - Homo sapiens (human) | 2 | 1024 | 5 | 25249 | 2.81e-02 | 0.00 | 0.00 | 9.8 |
352 | 140834 | Extrinsic Pathway | 2 | 1024 | 5 | 25249 | 2.81e-02 | 0.00 | 0.00 | 9.8 |
353 | 74230 | dATP formation | 2 | 1024 | 5 | 25249 | 2.81e-02 | 0.00 | 0.00 | 9.8 |
354 | 76003 | Presynaptic phase of homologous DNA pairing and strand exchange | 2 | 1024 | 5 | 25249 | 2.81e-02 | 0.00 | 0.00 | 9.8 |
355 | 74259 | Purine catabolism | 2 | 1024 | 5 | 25249 | 2.81e-02 | 0.00 | 0.00 | 9.8 |
356 | hsa00361 | gamma-Hexachlorocyclohexane degradation - Homo sapiens (human) | 4 | 1022 | 26 | 25228 | 2.82e-02 | 0.00 | 0.00 | 3.8 |
357 | 164952 | The role of Nef in HIV-1 replication and disease pathogenesis | 4 | 1022 | 28 | 25226 | 3.49e-02 | 0.00 | 0.00 | 3.5 |
358 | hsa05110 | Cholera - Infection - Homo sapiens (human) | 5 | 1021 | 42 | 25212 | 3.56e-02 | 0.00 | 0.00 | 2.9 |
359 | hsa04340 | Hedgehog signaling pathway - Homo sapiens (human) | 6 | 1020 | 57 | 25197 | 3.60e-02 | 0.01 | 0.00 | 2.6 |
360 | 166166 | TRAM Cascade | 2 | 1024 | 6 | 25248 | 3.65e-02 | 0.00 | 0.00 | 8.2 |
361 | 114664 | G alpha 12 cascade | 2 | 1024 | 6 | 25248 | 3.65e-02 | 0.00 | 0.00 | 8.2 |
362 | hsa00061 | Fatty acid biosynthesis - Homo sapiens (human) | 2 | 1024 | 6 | 25248 | 3.65e-02 | 0.00 | 0.00 | 8.2 |
363 | 168253 | Host Interactions with Influenza Factors | 2 | 1024 | 6 | 25248 | 3.65e-02 | 0.00 | 0.00 | 8.2 |
364 | hsa00632 | Benzoate degradation via CoA ligation - Homo sapiens (human) | 4 | 1022 | 29 | 25225 | 3.85e-02 | 0.00 | 0.00 | 3.4 |
365 | hsa04140 | Regulation of autophagy - Homo sapiens (human) | 4 | 1022 | 29 | 25225 | 3.85e-02 | 0.00 | 0.00 | 3.4 |
366 | hsa00531 | Glycosaminoglycan degradation - Homo sapiens (human) | 3 | 1023 | 17 | 25237 | 4.12e-02 | 0.00 | 0.00 | 4.3 |
367 | 70895 | Branched-chain amino acid catabolism | 3 | 1023 | 17 | 25237 | 4.12e-02 | 0.00 | 0.00 | 4.3 |
368 | hsa04330 | Notch signaling pathway - Homo sapiens (human) | 5 | 1021 | 45 | 25209 | 4.48e-02 | 0.00 | 0.00 | 2.7 |
369 | 74182 | Ketone body metabolism | 2 | 1024 | 7 | 25247 | 4.57e-02 | 0.00 | 0.00 | 7.0 |
370 | 164944 | Nef and signal transduction | 2 | 1024 | 7 | 25247 | 4.57e-02 | 0.00 | 0.00 | 7.0 |
371 | 114604 | Collagen-mediated activation cascade | 2 | 1024 | 7 | 25247 | 4.57e-02 | 0.00 | 0.00 | 7.0 |
372 | 110097 | Reversible phosphorylation of nucleoside monophosphates | 2 | 1024 | 7 | 25247 | 4.57e-02 | 0.00 | 0.00 | 7.0 |
373 | 142033 | Ethanol Catabolism | 2 | 1024 | 7 | 25247 | 4.57e-02 | 0.00 | 0.00 | 7.0 |
374 | 76604 | Ribonucleotide salvage | 2 | 1024 | 7 | 25247 | 4.57e-02 | 0.00 | 0.00 | 7.0 |
375 | hsa00565 | Ether lipid metabolism - Homo sapiens (human) | 4 | 1022 | 31 | 25223 | 4.64e-02 | 0.00 | 0.00 | 3.2 |
376 | 192076 | Steroid metabolism | 6 | 1020 | 61 | 25193 | 4.64e-02 | 0.01 | 0.00 | 2.4 |
377 | 114452 | Activation of BH3-only proteins | 3 | 1023 | 18 | 25236 | 4.67e-02 | 0.00 | 0.00 | 4.1 |
378 | 162909 | Host Interactions of HIV factors | 7 | 1019 | 78 | 25176 | 4.84e-02 | 0.01 | 0.00 | 2.2 |
379 | 168799 | Botulinum neurotoxicity | 3 | 1023 | 19 | 25235 | 0.05 | 0.00 | 0.00 | 3.9 |
380 | 68962 | Activation of the pre-replicative complex | 4 | 1022 | 33 | 25221 | 0.06 | 0.00 | 0.00 | 3.0 |
381 | 74217 | Purine salvage reactions | 2 | 1024 | 8 | 25246 | 0.06 | 0.00 | 0.00 | 6.2 |
382 | 190370 | FGFR1b ligand binding and activation | 2 | 1024 | 8 | 25246 | 0.06 | 0.00 | 0.00 | 6.2 |
383 | 203615 | eNOS activation | 2 | 1024 | 8 | 25246 | 0.06 | 0.00 | 0.00 | 6.2 |
384 | 71336 | Pentose phosphate pathway (hexose monophosphate shunt) | 2 | 1024 | 8 | 25246 | 0.06 | 0.00 | 0.00 | 6.2 |
385 | hsa00460 | Cyanoamino acid metabolism - Homo sapiens (human) | 2 | 1024 | 8 | 25246 | 0.06 | 0.00 | 0.00 | 6.2 |
386 | 114711 | vWF interaction with collagen | 2 | 1024 | 8 | 25246 | 0.06 | 0.00 | 0.00 | 6.2 |
387 | 190377 | FGFR2b ligand binding and activation | 2 | 1024 | 8 | 25246 | 0.06 | 0.00 | 0.00 | 6.2 |
388 | 73848 | Pyrimidine metabolism | 3 | 1023 | 21 | 25233 | 0.07 | 0.00 | 0.00 | 3.5 |
389 | 70172 | Phosphorylase kinase activates glycogen phosphorylase | 2 | 1024 | 9 | 25245 | 0.07 | 0.00 | 0.00 | 5.5 |
390 | hsa00400 | Phenylalanine, tyrosine and tryptophan biosynthesis - Homo sapiens (human) | 2 | 1024 | 9 | 25245 | 0.07 | 0.00 | 0.00 | 5.5 |
391 | 111447 | Activation of BAD and translocation to mitochondria | 2 | 1024 | 9 | 25245 | 0.07 | 0.00 | 0.00 | 5.5 |
392 | 167021 | PLC-gamma1 signalling | 2 | 1024 | 9 | 25245 | 0.07 | 0.00 | 0.00 | 5.5 |
393 | 73648 | Pyrimidine biosynthesis (interconversion) | 2 | 1024 | 9 | 25245 | 0.07 | 0.00 | 0.00 | 5.5 |
394 | 164938 | Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters | 3 | 1023 | 22 | 25232 | 0.07 | 0.00 | 0.00 | 3.4 |
395 | 180786 | Extension of Telomeres | 3 | 1023 | 22 | 25232 | 0.07 | 0.00 | 0.00 | 3.4 |
396 | 109368 | Hydrolysis of cytosolic nucleoside 5'-monophosphates by 5'-nucleotidase cytosolic IA | 1 | 1025 | 1 | 25253 | 0.08 | 0.00 | 0.00 | 24.6 |
397 | 191650 | Regulation of gap junction activity | 1 | 1025 | 1 | 25253 | 0.08 | 0.00 | 0.00 | 24.6 |
398 | hsa00472 | D-Arginine and D-ornithine metabolism - Homo sapiens (human) | 1 | 1025 | 1 | 25253 | 0.08 | 0.00 | 0.00 | 24.6 |
399 | 140180 | COX reactions | 1 | 1025 | 1 | 25253 | 0.08 | 0.00 | 0.00 | 24.6 |
400 | 74243 | Hypoxanthine formation | 1 | 1025 | 1 | 25253 | 0.08 | 0.00 | 0.00 | 24.6 |
401 | 171052 | LDL endocytosis | 1 | 1025 | 1 | 25253 | 0.08 | 0.00 | 0.00 | 24.6 |
402 | 109471 | Hydrolysis of cytosolic nucleoside 5'- and 3'-monophosphates by 5',3'-nucleotidase, cytosolic | 1 | 1025 | 1 | 25253 | 0.08 | 0.00 | 0.00 | 24.6 |
403 | 71383 | Acetate, ATP, and coenzyme A react to form acetyl CoA, AMP, and pyrophosphate | 1 | 1025 | 1 | 25253 | 0.08 | 0.00 | 0.00 | 24.6 |
404 | 110056 | ERK1 activation | 1 | 1025 | 1 | 25253 | 0.08 | 0.00 | 0.00 | 24.6 |
405 | 112411 | ERK2 activation | 1 | 1025 | 1 | 25253 | 0.08 | 0.00 | 0.00 | 24.6 |
406 | 70105 | 1,3-bisphosphoglycerate and ADP react to form 3-phosphoglycerate and ATP | 1 | 1025 | 1 | 25253 | 0.08 | 0.00 | 0.00 | 24.6 |
407 | 181546 | BoNT Light Chain Types A, C1, E cleave SNAP-25 | 1 | 1025 | 1 | 25253 | 0.08 | 0.00 | 0.00 | 24.6 |
408 | 70109 | Dihydroxyacetone phosphate is isomerized to form glyceraldehyde-3-phosphate | 1 | 1025 | 1 | 25253 | 0.08 | 0.00 | 0.00 | 24.6 |
409 | 171319 | Telomere Extension By Telomerase | 1 | 1025 | 1 | 25253 | 0.08 | 0.00 | 0.00 | 24.6 |
410 | 109279 | Hydrolysis of extracellular nucleoside 5'-monophosphates by plasma membrane-bound 5'-nucleotidase | 1 | 1025 | 1 | 25253 | 0.08 | 0.00 | 0.00 | 24.6 |
411 | 70112 | Glucose 6-phosphate is isomerized to form fructose-6-phosphate | 1 | 1025 | 1 | 25253 | 0.08 | 0.00 | 0.00 | 24.6 |
412 | 193144 | Estrogen biosynthesis | 1 | 1025 | 1 | 25253 | 0.08 | 0.00 | 0.00 | 24.6 |
413 | 191647 | c-src mediated regulation of Cx43 function and closure of gap junctions | 1 | 1025 | 1 | 25253 | 0.08 | 0.00 | 0.00 | 24.6 |
414 | 199997 | COPI Mediated Transport | 2 | 1024 | 10 | 25244 | 0.08 | 0.00 | 0.00 | 4.9 |
415 | 70894 | Valine catabolism | 2 | 1024 | 10 | 25244 | 0.08 | 0.00 | 0.00 | 4.9 |
416 | 70845 | Isoleucine catabolism | 2 | 1024 | 10 | 25244 | 0.08 | 0.00 | 0.00 | 4.9 |
417 | 167590 | Nef Mediated CD4 Down-regulation | 2 | 1024 | 10 | 25244 | 0.08 | 0.00 | 0.00 | 4.9 |
418 | 199983 | Golgi to ER Retrograde Transport | 2 | 1024 | 10 | 25244 | 0.08 | 0.00 | 0.00 | 4.9 |
419 | hsa00120 | Bile acid biosynthesis - Homo sapiens (human) | 4 | 1022 | 39 | 25215 | 0.09 | 0.00 | 0.00 | 2.5 |
420 | hsa00910 | Nitrogen metabolism - Homo sapiens (human) | 3 | 1023 | 24 | 25230 | 0.09 | 0.00 | 0.00 | 3.1 |
421 | 69306 | DNA Replication | 8 | 1018 | 106 | 25148 | 0.09 | 0.01 | 0.00 | 1.9 |
422 | hsa00140 | C21-Steroid hormone metabolism - Homo sapiens (human) | 2 | 1024 | 11 | 25243 | 0.09 | 0.00 | 0.00 | 4.5 |
423 | hsa00500 | Starch and sucrose metabolism - Homo sapiens (human) | 7 | 1019 | 85 | 25169 | 0.09 | 0.01 | 0.00 | 2.0 |
424 | 201451 | Signaling by BMP | 3 | 1023 | 25 | 25229 | 0.09 | 0.00 | 0.00 | 3.0 |
425 | 69620 | Cell Cycle Checkpoints | 9 | 1017 | 119 | 25135 | 0.10 | 0.01 | 0.00 | 1.9 |
426 | hsa00290 | Valine, leucine and isoleucine biosynthesis - Homo sapiens (human) | 2 | 1024 | 12 | 25242 | 0.10 | 0.00 | 0.00 | 4.1 |
427 | 196071 | Steroid hormone biosynthesis | 2 | 1024 | 12 | 25242 | 0.10 | 0.00 | 0.00 | 4.1 |
428 | 165159 | mTOR signalling | 2 | 1024 | 12 | 25242 | 0.10 | 0.00 | 0.00 | 4.1 |
429 | 109703 | PKB-mediated events | 2 | 1024 | 12 | 25242 | 0.10 | 0.00 | 0.00 | 4.1 |
430 | 203765 | eNOS activation and regulation | 2 | 1024 | 12 | 25242 | 0.10 | 0.00 | 0.00 | 4.1 |
431 | 72649 | Translation initiation complex formation | 5 | 1021 | 59 | 25195 | 0.10 | 0.00 | 0.00 | 2.1 |
432 | 72662 | Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S | 5 | 1021 | 60 | 25194 | 0.11 | 0.00 | 0.00 | 2.1 |
433 | 168769 | BoNT Light Chain Types B, D, and F cleave VAMP/Synaptobrevin | 1 | 1025 | 2 | 25252 | 0.11 | 0.00 | 0.00 | 12.3 |
434 | 73728 | RNA Polymerase I Promoter Opening | 1 | 1025 | 2 | 25252 | 0.11 | 0.00 | 0.00 | 12.3 |
435 | 140188 | P450 Dehalogenation | 1 | 1025 | 2 | 25252 | 0.11 | 0.00 | 0.00 | 12.3 |
436 | 169131 | Inhibition of PKR | 1 | 1025 | 2 | 25252 | 0.11 | 0.00 | 0.00 | 12.3 |
437 | 75854 | Formation of Acetyl-FAS on one FAS monomer | 1 | 1025 | 2 | 25252 | 0.11 | 0.00 | 0.00 | 12.3 |
438 | 74236 | Inosine formation | 1 | 1025 | 2 | 25252 | 0.11 | 0.00 | 0.00 | 12.3 |
439 | 163765 | ChREBP activates metabolic gene expression | 1 | 1025 | 2 | 25252 | 0.11 | 0.00 | 0.00 | 12.3 |
440 | 111495 | Conversion of cytosolic inosine 5'-monophosphate, L-aspartate, and GTP to adenylosuccinate, guanosine 5'-diphosphate, and orthophosphate | 1 | 1025 | 2 | 25252 | 0.11 | 0.00 | 0.00 | 12.3 |
441 | 141333 | Monoamines are oxidized to aldehydes, producing NH3 and H2O2 | 1 | 1025 | 2 | 25252 | 0.11 | 0.00 | 0.00 | 12.3 |
442 | hsa00902 | Monoterpenoid biosynthesis - Homo sapiens (human) | 1 | 1025 | 2 | 25252 | 0.11 | 0.00 | 0.00 | 12.3 |
443 | 142048 | Aldehyde Dehydrogenase | 1 | 1025 | 2 | 25252 | 0.11 | 0.00 | 0.00 | 12.3 |
444 | 70525 | Alanine metabolism | 1 | 1025 | 2 | 25252 | 0.11 | 0.00 | 0.00 | 12.3 |
445 | 114294 | Activation, translocation and oligomerization of BAX | 1 | 1025 | 2 | 25252 | 0.11 | 0.00 | 0.00 | 12.3 |
446 | 110131 | Reversible phosphorylation of mitochondrial nucleoside monophosphates by adenylate kinase 2 | 1 | 1025 | 2 | 25252 | 0.11 | 0.00 | 0.00 | 12.3 |
447 | 163754 | Insulin effects increased synthesis of Xylulose-5-Phosphate | 1 | 1025 | 2 | 25252 | 0.11 | 0.00 | 0.00 | 12.3 |
448 | 168277 | Influenza Virus Induced Apoptosis | 1 | 1025 | 2 | 25252 | 0.11 | 0.00 | 0.00 | 12.3 |
449 | 110123 | Reversible phosphorylation of cytosolic nucleoside monophosphates by adenylate kinase 1 | 1 | 1025 | 2 | 25252 | 0.11 | 0.00 | 0.00 | 12.3 |
450 | hsa00031 | Inositol metabolism - Homo sapiens (human) | 1 | 1025 | 2 | 25252 | 0.11 | 0.00 | 0.00 | 12.3 |
451 | 156579 | P450 oxidation | 1 | 1025 | 2 | 25252 | 0.11 | 0.00 | 0.00 | 12.3 |
452 | 111452 | Activation and oligomerization of BAK protein | 1 | 1025 | 2 | 25252 | 0.11 | 0.00 | 0.00 | 12.3 |
453 | 71364 | Acetaldehyde is oxidized by NAD+ to form acetate, NADH, and H+ | 1 | 1025 | 2 | 25252 | 0.11 | 0.00 | 0.00 | 12.3 |
454 | 198745 | Signalling to STAT3 | 1 | 1025 | 2 | 25252 | 0.11 | 0.00 | 0.00 | 12.3 |
455 | 69481 | G2/M Checkpoints | 4 | 1022 | 44 | 25210 | 0.12 | 0.00 | 0.00 | 2.2 |
456 | 194068 | Metabolism of bile acids and bile salts | 3 | 1023 | 28 | 25226 | 0.12 | 0.00 | 0.00 | 2.6 |
457 | 194315 | Signaling by Rho GTPases | 9 | 1017 | 132 | 25122 | 0.13 | 0.01 | 0.01 | 1.7 |
458 | 69166 | Removal of the Flap Intermediate | 2 | 1024 | 14 | 25240 | 0.13 | 0.00 | 0.00 | 3.5 |
459 | 73951 | Homologous recombination repair of replication-independent double-strand breaks | 2 | 1024 | 14 | 25240 | 0.13 | 0.00 | 0.00 | 3.5 |
460 | hsa00603 | Glycosphingolipid biosynthesis - globoseries - Homo sapiens (human) | 2 | 1024 | 14 | 25240 | 0.13 | 0.00 | 0.00 | 3.5 |
461 | 73888 | Homologous Recombination Repair | 2 | 1024 | 14 | 25240 | 0.13 | 0.00 | 0.00 | 3.5 |
462 | 210500 | Neuronal Glutamate cycle | 2 | 1024 | 14 | 25240 | 0.13 | 0.00 | 0.00 | 3.5 |
463 | 69183 | Processive synthesis on the lagging strand | 2 | 1024 | 14 | 25240 | 0.13 | 0.00 | 0.00 | 3.5 |
464 | hsa01032 | Glycan structures - degradation - Homo sapiens (human) | 3 | 1023 | 29 | 25225 | 0.13 | 0.00 | 0.00 | 2.5 |
465 | 157858 | Gap junction trafficking and regulation | 3 | 1023 | 29 | 25225 | 0.13 | 0.00 | 0.00 | 2.5 |
466 | hsa00450 | Selenoamino acid metabolism - Homo sapiens (human) | 3 | 1023 | 30 | 25224 | 0.14 | 0.00 | 0.00 | 2.5 |
467 | hsa00641 | 3-Chloroacrylic acid degradation - Homo sapiens (human) | 2 | 1024 | 15 | 25239 | 0.14 | 0.00 | 0.00 | 3.3 |
468 | 69091 | Polymerase switching | 2 | 1024 | 15 | 25239 | 0.14 | 0.00 | 0.00 | 3.3 |
469 | 69109 | Leading Strand Synthesis | 2 | 1024 | 15 | 25239 | 0.14 | 0.00 | 0.00 | 3.3 |
470 | 174411 | Polymerase switching on the C-strand of the telomere | 2 | 1024 | 15 | 25239 | 0.14 | 0.00 | 0.00 | 3.3 |
471 | hsa00530 | Aminosugars metabolism - Homo sapiens (human) | 3 | 1023 | 31 | 25223 | 0.15 | 0.00 | 0.00 | 2.4 |
472 | 254954 | PI3K/AKT signalling | 1 | 1025 | 3 | 25251 | 0.15 | 0.00 | 0.00 | 8.2 |
473 | 163767 | PP2A-mediated dephosphorylation of key metabolic factors | 1 | 1025 | 3 | 25251 | 0.15 | 0.00 | 0.00 | 8.2 |
474 | 111742 | Reduction of cytosolic ribonucleoside 5'-diphosphates to deoxyribonucleoside 5'-diphosphates (glutaredoxin) | 1 | 1025 | 3 | 25251 | 0.15 | 0.00 | 0.00 | 8.2 |
475 | hsa00401 | Novobiocin biosynthesis - Homo sapiens (human) | 1 | 1025 | 3 | 25251 | 0.15 | 0.00 | 0.00 | 8.2 |
476 | 254774 | Signalling by NGF | 1 | 1025 | 3 | 25251 | 0.15 | 0.00 | 0.00 | 8.2 |
477 | 140179 | Amine Oxidase reactions | 1 | 1025 | 3 | 25251 | 0.15 | 0.00 | 0.00 | 8.2 |
478 | 254985 | AKT phosphorylates targets in the cytosol | 1 | 1025 | 3 | 25251 | 0.15 | 0.00 | 0.00 | 8.2 |
479 | 180534 | Vpu mediated degradation of CD4 | 1 | 1025 | 3 | 25251 | 0.15 | 0.00 | 0.00 | 8.2 |
480 | 166144 | Mal Cascade | 1 | 1025 | 3 | 25251 | 0.15 | 0.00 | 0.00 | 8.2 |
481 | 73927 | Depurination | 1 | 1025 | 3 | 25251 | 0.15 | 0.00 | 0.00 | 8.2 |
482 | 166662 | Lectin pathway of complement activation | 1 | 1025 | 3 | 25251 | 0.15 | 0.00 | 0.00 | 8.2 |
483 | 70853 | Oxidative decarboxylation of alpha-ketoisovalerate to isobutyryl-CoA by branched-chain alpha-ketoacid dehydrogenase | 1 | 1025 | 3 | 25251 | 0.15 | 0.00 | 0.00 | 8.2 |
484 | 114593 | Collagen adhesion via Gp IV | 1 | 1025 | 3 | 25251 | 0.15 | 0.00 | 0.00 | 8.2 |
485 | 111747 | Reduction of cytosolic ribonucleoside 5'-diphosphates to deoxyribonucleoside 5'-diphosphates by ribonucleotide reductase and glutaredoxin | 1 | 1025 | 3 | 25251 | 0.15 | 0.00 | 0.00 | 8.2 |
486 | 139910 | Activation of BMF and translocation to mitochondria | 1 | 1025 | 3 | 25251 | 0.15 | 0.00 | 0.00 | 8.2 |
487 | 75899 | Conversion of Phosphatidic Acid to Diacylglycerol | 1 | 1025 | 3 | 25251 | 0.15 | 0.00 | 0.00 | 8.2 |
488 | 110330 | Recognition and association of DNA glycosylase with site containing an affected purine | 1 | 1025 | 3 | 25251 | 0.15 | 0.00 | 0.00 | 8.2 |
489 | 254773 | TRKA signalling from the plasma membrane | 1 | 1025 | 3 | 25251 | 0.15 | 0.00 | 0.00 | 8.2 |
490 | 110331 | Cleavage of the damaged purine | 1 | 1025 | 3 | 25251 | 0.15 | 0.00 | 0.00 | 8.2 |
491 | 70726 | Oxidative decarboxylation of alpha-ketoisocaproate to isovaleryl-CoA by branched-chain alpha-ketoacid dehydrogenase | 1 | 1025 | 3 | 25251 | 0.15 | 0.00 | 0.00 | 8.2 |
492 | 69541 | Stabilization of p53 | 1 | 1025 | 3 | 25251 | 0.15 | 0.00 | 0.00 | 8.2 |
493 | 71032 | Propionyl-CoA catabolism | 1 | 1025 | 3 | 25251 | 0.15 | 0.00 | 0.00 | 8.2 |
494 | 165181 | Inhibition of TSC complex formation by PKB | 1 | 1025 | 3 | 25251 | 0.15 | 0.00 | 0.00 | 8.2 |
495 | 70794 | Oxidative decarboxylation of alpha-keto-beta-methylvalerate to alpha-methylbutyryl-CoA by branched-chain alpha-ketoacid dehydrogenase | 1 | 1025 | 3 | 25251 | 0.15 | 0.00 | 0.00 | 8.2 |
496 | hsa00670 | One carbon pool by folate - Homo sapiens (human) | 2 | 1024 | 16 | 25238 | 0.15 | 0.00 | 0.00 | 3.1 |
497 | hsa00053 | Ascorbate and aldarate metabolism - Homo sapiens (human) | 2 | 1024 | 16 | 25238 | 0.15 | 0.00 | 0.00 | 3.1 |
498 | hsa00740 | Riboflavin metabolism - Homo sapiens (human) | 2 | 1024 | 16 | 25238 | 0.15 | 0.00 | 0.00 | 3.1 |
499 | 69190 | DNA strand elongation | 3 | 1023 | 32 | 25222 | 0.16 | 0.00 | 0.00 | 2.3 |
500 | 212436 | Generic Transcription Pathway | 2 | 1024 | 17 | 25237 | 0.17 | 0.00 | 0.00 | 2.9 |
501 | 73890 | Double-Strand Break Repair | 2 | 1024 | 17 | 25237 | 0.17 | 0.00 | 0.00 | 2.9 |
502 | hsa00272 | Cysteine metabolism - Homo sapiens (human) | 2 | 1024 | 17 | 25237 | 0.17 | 0.00 | 0.00 | 2.9 |
503 | 70216 | Poly{(1,4)-alpha-glucosyl} glycogenin reacts with n orthophosphates to form glycogenin and n D-glucose 1-phosphates | 1 | 1025 | 4 | 25250 | 0.18 | 0.00 | 0.00 | 6.2 |
504 | 69610 | p53-Independent DNA Damage Response | 1 | 1025 | 4 | 25250 | 0.18 | 0.00 | 0.00 | 6.2 |
505 | hsa00830 | Retinol metabolism - Homo sapiens (human) | 1 | 1025 | 4 | 25250 | 0.18 | 0.00 | 0.00 | 6.2 |
506 | 196843 | Vitamin B2 (riboflavin) metabolism | 1 | 1025 | 4 | 25250 | 0.18 | 0.00 | 0.00 | 6.2 |
507 | 77288 | mitochondrial fatty acid beta-oxidation of unsaturated fatty acids | 1 | 1025 | 4 | 25250 | 0.18 | 0.00 | 0.00 | 6.2 |
508 | 166786 | Creation of C4 and C2 activators | 1 | 1025 | 4 | 25250 | 0.18 | 0.00 | 0.00 | 6.2 |
509 | 68911 | G2 Phase | 1 | 1025 | 4 | 25250 | 0.18 | 0.00 | 0.00 | 6.2 |
510 | 76605 | Deoxyribonucleotide salvage | 1 | 1025 | 4 | 25250 | 0.18 | 0.00 | 0.00 | 6.2 |
511 | 70182 | Glycogen-glycogenin reacts with n orthophosphates, yielding n glucose 1-phosphates and limit dextrin-glycogenin | 1 | 1025 | 4 | 25250 | 0.18 | 0.00 | 0.00 | 6.2 |
512 | 69601 | Ubiquitin Mediated Degradation of Phosphorylated Cdc25A | 1 | 1025 | 4 | 25250 | 0.18 | 0.00 | 0.00 | 6.2 |
513 | 168276 | NS1 Mediated Effects on Host Pathways | 1 | 1025 | 4 | 25250 | 0.18 | 0.00 | 0.00 | 6.2 |
514 | 77305 | Beta oxidation of palmitoyl-CoA to myristoyl-CoA | 1 | 1025 | 4 | 25250 | 0.18 | 0.00 | 0.00 | 6.2 |
515 | 69613 | p53-Independent G1/S DNA damage checkpoint | 1 | 1025 | 4 | 25250 | 0.18 | 0.00 | 0.00 | 6.2 |
516 | 196299 | Beta-catenin phosphorylation cascade | 1 | 1025 | 4 | 25250 | 0.18 | 0.00 | 0.00 | 6.2 |
517 | 111446 | Activation of BIM and translocation to mitochondria | 1 | 1025 | 4 | 25250 | 0.18 | 0.00 | 0.00 | 6.2 |
518 | 140189 | P450 Dehydrogenation of alkanes to form alkenes | 1 | 1025 | 4 | 25250 | 0.18 | 0.00 | 0.00 | 6.2 |
519 | 200425 | Import of palmitoyl-CoA into the mitochondrial matrix | 1 | 1025 | 4 | 25250 | 0.18 | 0.00 | 0.00 | 6.2 |
520 | 168936 | Viral dsRNA:TLR3:TRIF Complex Activates TBK1 | 1 | 1025 | 4 | 25250 | 0.18 | 0.00 | 0.00 | 6.2 |
521 | 77285 | Beta oxidation of myristoyl-CoA to lauroyl-CoA | 1 | 1025 | 4 | 25250 | 0.18 | 0.00 | 0.00 | 6.2 |
522 | 176187 | Activation of ATR in response to replication stress | 3 | 1023 | 36 | 25218 | 0.19 | 0.00 | 0.00 | 2.1 |
523 | 69186 | Lagging Strand Synthesis | 2 | 1024 | 19 | 25235 | 0.20 | 0.00 | 0.00 | 2.6 |
524 | 192105 | Synthesis of bile acids and bile salts | 2 | 1024 | 20 | 25234 | 0.21 | 0.00 | 0.00 | 2.5 |
525 | hsa00300 | Lysine biosynthesis - Homo sapiens (human) | 1 | 1025 | 5 | 25249 | 0.21 | 0.00 | 0.00 | 4.9 |
526 | 70108 | Glyceraldehyde 3-phosphate, NAD+, and orthophosphate react to form 1,3-bisphosphoglycerate, NADH, and H+ | 1 | 1025 | 5 | 25249 | 0.21 | 0.00 | 0.00 | 4.9 |
527 | 187015 | Activation of TRKA receptors | 1 | 1025 | 5 | 25249 | 0.21 | 0.00 | 0.00 | 4.9 |
528 | hsa00750 | Vitamin B6 metabolism - Homo sapiens (human) | 1 | 1025 | 5 | 25249 | 0.21 | 0.00 | 0.00 | 4.9 |
529 | 75108 | Activation, myristolyation of BID and translocation to mitochondria | 1 | 1025 | 5 | 25249 | 0.21 | 0.00 | 0.00 | 4.9 |
530 | 71338 | Ethanol is oxidized by NAD+ to form acetaldehyde, NADH, and H+ | 1 | 1025 | 5 | 25249 | 0.21 | 0.00 | 0.00 | 4.9 |
531 | 203927 | MicroRNA biogenesis | 1 | 1025 | 5 | 25249 | 0.21 | 0.00 | 0.00 | 4.9 |
532 | 71240 | Tryptophan catabolism | 1 | 1025 | 5 | 25249 | 0.21 | 0.00 | 0.00 | 4.9 |
533 | 165720 | S6K1 signalling | 1 | 1025 | 5 | 25249 | 0.21 | 0.00 | 0.00 | 4.9 |
534 | 142045 | Alcohol Dehydrogenase | 1 | 1025 | 5 | 25249 | 0.21 | 0.00 | 0.00 | 4.9 |
535 | 187024 | NGF-independant TRKA activation | 1 | 1025 | 5 | 25249 | 0.21 | 0.00 | 0.00 | 4.9 |
536 | 69478 | G2/M DNA replication checkpoint | 1 | 1025 | 5 | 25249 | 0.21 | 0.00 | 0.00 | 4.9 |
537 | 113510 | E2F mediated regulation of DNA replication | 2 | 1024 | 21 | 25233 | 0.23 | 0.00 | 0.00 | 2.3 |
538 | 199991 | Membrane Trafficking | 2 | 1024 | 21 | 25233 | 0.23 | 0.00 | 0.00 | 2.3 |
539 | 174417 | Telomere C-strand (Lagging Strand) Synthesis | 2 | 1024 | 21 | 25233 | 0.23 | 0.00 | 0.00 | 2.3 |
540 | 68867 | Assembly of the pre-replicative complex | 2 | 1024 | 22 | 25232 | 0.24 | 0.00 | 0.00 | 2.2 |
541 | 68874 | M/G1 Transition | 2 | 1024 | 22 | 25232 | 0.24 | 0.00 | 0.00 | 2.2 |
542 | 196757 | Metabolism of folate and pterines | 1 | 1025 | 6 | 25248 | 0.24 | 0.00 | 0.00 | 4.1 |
543 | 75035 | Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex | 1 | 1025 | 6 | 25248 | 0.24 | 0.00 | 0.00 | 4.1 |
544 | 163358 | PKA-mediated phosphorylation of key metabolic factors | 1 | 1025 | 6 | 25248 | 0.24 | 0.00 | 0.00 | 4.1 |
545 | 69200 | Phosphorylation of proteins involved in G1/S transition by active Cyclin E:Cdk2 complexes | 1 | 1025 | 6 | 25248 | 0.24 | 0.00 | 0.00 | 4.1 |
546 | 194002 | Glucocorticoid biosynthesis | 1 | 1025 | 6 | 25248 | 0.24 | 0.00 | 0.00 | 4.1 |
547 | hsa00340 | Histidine metabolism - Homo sapiens (human) | 3 | 1023 | 42 | 25212 | 0.26 | 0.00 | 0.00 | 1.8 |
548 | hsa00100 | Biosynthesis of steroids - Homo sapiens (human) | 2 | 1024 | 24 | 25230 | 0.27 | 0.00 | 0.00 | 2.1 |
549 | 166207 | S6K1-mediated signalling | 1 | 1025 | 7 | 25247 | 0.27 | 0.00 | 0.00 | 3.5 |
550 | 195253 | Degradation of beta-catenin by the destruction complex | 1 | 1025 | 7 | 25247 | 0.27 | 0.00 | 0.00 | 3.5 |
551 | 176417 | Phosphorylation of Emi1 | 1 | 1025 | 7 | 25247 | 0.27 | 0.00 | 0.00 | 3.5 |
552 | 167242 | Abortive elongation of HIV-1 transcript in the absence of Tat | 1 | 1025 | 7 | 25247 | 0.27 | 0.00 | 0.00 | 3.5 |
553 | 73614 | Pyrimidine salvage reactions | 1 | 1025 | 7 | 25247 | 0.27 | 0.00 | 0.00 | 3.5 |
554 | hsa00232 | Caffeine metabolism - Homo sapiens (human) | 1 | 1025 | 7 | 25247 | 0.27 | 0.00 | 0.00 | 3.5 |
555 | 72695 | Formation of the ternary complex, and subsequently, the 43S complex | 4 | 1022 | 52 | 25202 | 0.28 | 0.00 | 0.00 | 1.9 |
556 | hsa00624 | 1- and 2-Methylnaphthalene degradation - Homo sapiens (human) | 2 | 1024 | 25 | 25229 | 0.28 | 0.00 | 0.00 | 2.0 |
557 | hsa00040 | Pentose and glucuronate interconversions - Homo sapiens (human) | 2 | 1024 | 25 | 25229 | 0.28 | 0.00 | 0.00 | 2.0 |
558 | hsa00150 | Androgen and estrogen metabolism - Homo sapiens (human) | 4 | 1022 | 56 | 25198 | 0.30 | 0.00 | 0.00 | 1.8 |
559 | hsa03030 | DNA replication - Homo sapiens (human) | 2 | 1024 | 26 | 25228 | 0.30 | 0.00 | 0.00 | 1.9 |
560 | 70635 | Urea synthesis | 1 | 1025 | 8 | 25246 | 0.30 | 0.00 | 0.00 | 3.1 |
561 | 174414 | Processive synthesis on the C-strand of the telomere | 1 | 1025 | 8 | 25246 | 0.30 | 0.00 | 0.00 | 3.1 |
562 | 166663 | Initial triggering of complement | 1 | 1025 | 8 | 25246 | 0.30 | 0.00 | 0.00 | 3.1 |
563 | 159231 | Transport of Mature mRNA Derived from an Intronless Transcript | 1 | 1025 | 8 | 25246 | 0.30 | 0.00 | 0.00 | 3.1 |
564 | 68952 | DNA replication initiation | 1 | 1025 | 8 | 25246 | 0.30 | 0.00 | 0.00 | 3.1 |
565 | hsa00625 | Tetrachloroethene degradation - Homo sapiens (human) | 1 | 1025 | 8 | 25246 | 0.30 | 0.00 | 0.00 | 3.1 |
566 | hsa00130 | Ubiquinone biosynthesis - Homo sapiens (human) | 1 | 1025 | 8 | 25246 | 0.30 | 0.00 | 0.00 | 3.1 |
567 | 73929 | Base-Excision Repair, AP Site Formation | 1 | 1025 | 8 | 25246 | 0.30 | 0.00 | 0.00 | 3.1 |
568 | 70693 | Ornithine metabolism | 1 | 1025 | 8 | 25246 | 0.30 | 0.00 | 0.00 | 3.1 |
569 | 174437 | Removal of the Flap Intermediate from the C-strand | 1 | 1025 | 8 | 25246 | 0.30 | 0.00 | 0.00 | 3.1 |
570 | 72731 | Recycling of eIF2:GDP | 1 | 1025 | 8 | 25246 | 0.30 | 0.00 | 0.00 | 3.1 |
571 | 111453 | BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members | 1 | 1025 | 8 | 25246 | 0.30 | 0.00 | 0.00 | 3.1 |
572 | 174430 | Telomere C-strand synthesis initiation | 1 | 1025 | 8 | 25246 | 0.30 | 0.00 | 0.00 | 3.1 |
573 | 70302 | Glycogen synthesis | 1 | 1025 | 8 | 25246 | 0.30 | 0.00 | 0.00 | 3.1 |
574 | 72702 | Ribosomal scanning and start codon recognition | 4 | 1022 | 59 | 25195 | 0.31 | 0.00 | 0.00 | 1.7 |
575 | 157279 | 3' -UTR-mediated translational regulation | 6 | 1020 | 103 | 25151 | 0.32 | 0.01 | 0.00 | 1.4 |
576 | 156827 | L13a-mediated translational silencing of Ceruloplasmin expression | 6 | 1020 | 103 | 25151 | 0.32 | 0.01 | 0.00 | 1.4 |
577 | 176408 | Regulation of APC/C activators between G1/S and early anaphase | 2 | 1024 | 28 | 25226 | 0.33 | 0.00 | 0.00 | 1.8 |
578 | 166208 | mTORC1-mediated signalling | 1 | 1025 | 9 | 25245 | 0.33 | 0.00 | 0.00 | 2.7 |
579 | hsa00072 | Synthesis and degradation of ketone bodies - Homo sapiens (human) | 1 | 1025 | 9 | 25245 | 0.33 | 0.00 | 0.00 | 2.7 |
580 | 70793 | Leucine catabolism | 1 | 1025 | 9 | 25245 | 0.33 | 0.00 | 0.00 | 2.7 |
581 | 110357 | Displacement of DNA glycosylase by APE1 | 1 | 1025 | 9 | 25245 | 0.33 | 0.00 | 0.00 | 2.7 |
582 | 189451 | Heme biosynthesis | 1 | 1025 | 9 | 25245 | 0.33 | 0.00 | 0.00 | 2.7 |
583 | 176033 | Interactions of Vpr with host cellular proteins | 2 | 1024 | 29 | 25225 | 0.34 | 0.00 | 0.00 | 1.7 |
584 | 164940 | Nef mediated downregulation of MHC class I complex cell surface expression | 1 | 1025 | 10 | 25244 | 0.35 | 0.00 | 0.00 | 2.5 |
585 | 199220 | Vitamin B5 (pantothenate) metabolism | 1 | 1025 | 10 | 25244 | 0.35 | 0.00 | 0.00 | 2.5 |
586 | 159234 | Transport of Mature mRNAs Derived from Intronless Transcripts | 1 | 1025 | 10 | 25244 | 0.35 | 0.00 | 0.00 | 2.5 |
587 | 73930 | Base-free sugar-phosphate removal via the single-nucleotide replacement pathway | 1 | 1025 | 10 | 25244 | 0.35 | 0.00 | 0.00 | 2.5 |
588 | 189445 | Porphyrin metabolism | 1 | 1025 | 10 | 25244 | 0.35 | 0.00 | 0.00 | 2.5 |
589 | 156584 | Cytosolic sulfonation of small molecules | 1 | 1025 | 10 | 25244 | 0.35 | 0.00 | 0.00 | 2.5 |
590 | 113501 | Inhibition of replication initiation of damaged DNA by Rb/E2F1 | 1 | 1025 | 10 | 25244 | 0.35 | 0.00 | 0.00 | 2.5 |
591 | 69473 | G2/M DNA damage checkpoint | 1 | 1025 | 10 | 25244 | 0.35 | 0.00 | 0.00 | 2.5 |
592 | hsa04740 | Olfactory transduction - Homo sapiens (human) | 2 | 1024 | 31 | 25223 | 0.37 | 0.00 | 0.00 | 1.6 |
593 | 174143 | APC/C-mediated degradation of cell cycle proteins | 2 | 1024 | 31 | 25223 | 0.37 | 0.00 | 0.00 | 1.6 |
594 | 162599 | Late Phase of HIV Life Cycle | 1 | 1025 | 75 | 25179 | 0.37 | 0.00 | 0.00 | 0.3 |
595 | 77595 | Processing of Intronless Pre-mRNAs | 1 | 1025 | 11 | 25243 | 0.38 | 0.00 | 0.00 | 2.2 |
596 | 110381 | Resolution of AP sites via the single-nucleotide replacement pathway | 1 | 1025 | 11 | 25243 | 0.38 | 0.00 | 0.00 | 2.2 |
597 | 113507 | E2F-enabled inhibition of pre-replication complex formation | 1 | 1025 | 11 | 25243 | 0.38 | 0.00 | 0.00 | 2.2 |
598 | 191345 | Transformation of lanosterol to cholesterol | 1 | 1025 | 11 | 25243 | 0.38 | 0.00 | 0.00 | 2.2 |
599 | 69298 | Association of licensing factors with the pre-replicative complex | 1 | 1025 | 11 | 25243 | 0.38 | 0.00 | 0.00 | 2.2 |
600 | 75071 | mRNA Processing | 3 | 1023 | 145 | 25109 | 0.39 | 0.00 | 0.01 | 0.5 |
601 | 156902 | Peptide chain elongation | 5 | 1021 | 83 | 25171 | 0.40 | 0.00 | 0.00 | 1.5 |
602 | 196807 | Nicotinate metabolism | 1 | 1025 | 12 | 25242 | 0.40 | 0.00 | 0.00 | 2.1 |
603 | 70694 | Ornithine and proline metabolism | 1 | 1025 | 12 | 25242 | 0.40 | 0.00 | 0.00 | 2.1 |
604 | 69273 | Cyclin A/B1 associated events during G2/M transition | 1 | 1025 | 12 | 25242 | 0.40 | 0.00 | 0.00 | 2.1 |
605 | 159418 | Recycling of bile acids and salts | 1 | 1025 | 12 | 25242 | 0.40 | 0.00 | 0.00 | 2.1 |
606 | 156842 | Eukaryotic Translation Elongation | 5 | 1021 | 86 | 25168 | 0.41 | 0.00 | 0.00 | 1.4 |
607 | 69275 | G2/M Transition | 1 | 1025 | 13 | 25241 | 0.43 | 0.00 | 0.00 | 1.9 |
608 | 68827 | CDT1 association with the CDC6:ORC:origin complex | 1 | 1025 | 13 | 25241 | 0.43 | 0.00 | 0.00 | 1.9 |
609 | 109977 | Repair synthesis for gap-filling by DNA polymerase in TC-NER | 1 | 1025 | 13 | 25241 | 0.43 | 0.00 | 0.00 | 1.9 |
610 | 74967 | Repair synthesis of patch ~27-30 bases long by DNA polymerase | 1 | 1025 | 13 | 25241 | 0.43 | 0.00 | 0.00 | 1.9 |
611 | 176974 | Unwinding of DNA | 1 | 1025 | 13 | 25241 | 0.43 | 0.00 | 0.00 | 1.9 |
612 | 163841 | Post-translational protein modification | 3 | 1023 | 44 | 25210 | 0.43 | 0.00 | 0.00 | 1.7 |
613 | 109979 | Gap-filling DNA repair synthesis and ligation in TC-NER | 1 | 1025 | 14 | 25240 | 0.45 | 0.00 | 0.00 | 1.8 |
614 | 74969 | Gap-filling DNA repair synthesis and ligation in GG-NER | 1 | 1025 | 14 | 25240 | 0.45 | 0.00 | 0.00 | 1.8 |
615 | 167290 | Pausing and recovery of HIV-1 elongation | 1 | 1025 | 14 | 25240 | 0.45 | 0.00 | 0.00 | 1.8 |
616 | 110362 | Removal of DNA patch containing abasic residue | 1 | 1025 | 14 | 25240 | 0.45 | 0.00 | 0.00 | 1.8 |
617 | hsa00920 | Sulfur metabolism - Homo sapiens (human) | 1 | 1025 | 14 | 25240 | 0.45 | 0.00 | 0.00 | 1.8 |
618 | 194840 | Rho GTPase cycle | 6 | 1020 | 106 | 25148 | 0.46 | 0.01 | 0.00 | 1.4 |
619 | 72613 | Eukaryotic Translation Initiation | 6 | 1020 | 111 | 25143 | 0.47 | 0.01 | 0.00 | 1.3 |
620 | 72737 | Cap-dependent Translation Initiation | 6 | 1020 | 111 | 25143 | 0.47 | 0.01 | 0.00 | 1.3 |
621 | 162906 | HIV Infection | 10 | 1016 | 197 | 25057 | 0.47 | 0.01 | 0.01 | 1.2 |
622 | 167238 | Pausing and recovery of Tat-mediated HIV-1 elongation | 1 | 1025 | 15 | 25239 | 0.47 | 0.00 | 0.00 | 1.6 |
623 | 110373 | Resolution of AP sites via the multiple-nucleotide patch replacement pathway | 1 | 1025 | 15 | 25239 | 0.47 | 0.00 | 0.00 | 1.6 |
624 | 167246 | Tat-mediated elongation of the HIV-1 transcript | 1 | 1025 | 15 | 25239 | 0.47 | 0.00 | 0.00 | 1.6 |
625 | 167243 | Tat-mediated HIV-1 elongation arrest and recovery | 1 | 1025 | 15 | 25239 | 0.47 | 0.00 | 0.00 | 1.6 |
626 | 166658 | Complement cascade | 1 | 1025 | 15 | 25239 | 0.47 | 0.00 | 0.00 | 1.6 |
627 | hsa00511 | N-Glycan degradation - Homo sapiens (human) | 1 | 1025 | 15 | 25239 | 0.47 | 0.00 | 0.00 | 1.6 |
628 | hsa00363 | Bisphenol A degradation - Homo sapiens (human) | 1 | 1025 | 15 | 25239 | 0.47 | 0.00 | 0.00 | 1.6 |
629 | 193368 | Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol | 1 | 1025 | 16 | 25238 | 0.49 | 0.00 | 0.00 | 1.5 |
630 | hsa00604 | Glycosphingolipid biosynthesis - ganglioseries - Homo sapiens (human) | 1 | 1025 | 16 | 25238 | 0.49 | 0.00 | 0.00 | 1.5 |
631 | 167287 | HIV-1 elongation arrest and recovery | 1 | 1025 | 16 | 25238 | 0.49 | 0.00 | 0.00 | 1.5 |
632 | 73933 | Resolution of Abasic Sites (AP sites) | 1 | 1025 | 16 | 25238 | 0.49 | 0.00 | 0.00 | 1.5 |
633 | 73884 | Base Excision Repair | 1 | 1025 | 16 | 25238 | 0.49 | 0.00 | 0.00 | 1.5 |
634 | 75983 | Formation and Maturation of mRNA Transcript | 3 | 1023 | 130 | 25124 | 0.50 | 0.00 | 0.01 | 0.6 |
635 | hsa00440 | Aminophosphonate metabolism - Homo sapiens (human) | 1 | 1025 | 17 | 25237 | 0.51 | 0.00 | 0.00 | 1.4 |
636 | 211000 | Regulatory RNA pathways | 1 | 1025 | 17 | 25237 | 0.51 | 0.00 | 0.00 | 1.4 |
637 | 182971 | EGFR downregulation | 1 | 1025 | 17 | 25237 | 0.51 | 0.00 | 0.00 | 1.4 |
638 | 176412 | Phosphorylation of the APC/C | 1 | 1025 | 18 | 25236 | 0.53 | 0.00 | 0.00 | 1.4 |
639 | hsa00534 | Heparan sulfate biosynthesis - Homo sapiens (human) | 1 | 1025 | 19 | 25235 | 0.55 | 0.00 | 0.00 | 1.3 |
640 | 174048 | APC/C:Cdc20 mediated degradation of Cyclin B | 1 | 1025 | 19 | 25235 | 0.55 | 0.00 | 0.00 | 1.3 |
641 | 73854 | RNA Polymerase I Promoter Clearance | 1 | 1025 | 19 | 25235 | 0.55 | 0.00 | 0.00 | 1.3 |
642 | hsa05020 | Parkinson's disease - Homo sapiens (human) | 1 | 1025 | 20 | 25234 | 0.57 | 0.00 | 0.00 | 1.2 |
643 | 73864 | RNA Polymerase I Transcription | 1 | 1025 | 20 | 25234 | 0.57 | 0.00 | 0.00 | 1.2 |
644 | 72764 | Eukaryotic Translation Termination | 4 | 1022 | 80 | 25174 | 0.57 | 0.00 | 0.00 | 1.2 |
645 | 191273 | Cholesterol biosynthesis | 1 | 1025 | 21 | 25233 | 0.58 | 0.00 | 0.00 | 1.2 |
646 | 72203 | Processing of Capped Intron-Containing Pre-mRNA | 2 | 1024 | 88 | 25166 | 0.59 | 0.00 | 0.00 | 0.6 |
647 | 73857 | RNA Polymerase II Transcription | 2 | 1024 | 91 | 25163 | 0.59 | 0.00 | 0.00 | 0.5 |
648 | 112168 | Processing of Capped pre-mRNA | 2 | 1024 | 92 | 25162 | 0.59 | 0.00 | 0.00 | 0.5 |
649 | 112297 | Post-Elongation Processing of Intronless pre-mRNA | 1 | 1025 | 22 | 25232 | 0.60 | 0.00 | 0.00 | 1.1 |
650 | 176409 | APC/C:Cdc20 mediated degradation of mitotic proteins | 1 | 1025 | 22 | 25232 | 0.60 | 0.00 | 0.00 | 1.1 |
651 | 75067 | Processing of Capped Intronless Pre-mRNA | 1 | 1025 | 22 | 25232 | 0.60 | 0.00 | 0.00 | 1.1 |
652 | 73894 | DNA Repair | 5 | 1021 | 100 | 25154 | 0.61 | 0.00 | 0.00 | 1.2 |
653 | 167158 | Formation of the HIV-1 Early Elongation Complex | 1 | 1025 | 23 | 25231 | 0.62 | 0.00 | 0.00 | 1.1 |
654 | hsa00563 | Glycosylphosphatidylinositol(GPI)-anchor biosynthesis - Homo sapiens (human) | 1 | 1025 | 23 | 25231 | 0.62 | 0.00 | 0.00 | 1.1 |
655 | 176814 | Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins | 1 | 1025 | 23 | 25231 | 0.62 | 0.00 | 0.00 | 1.1 |
656 | 72706 | GTP hydrolysis and joining of the 60S ribosomal subunit | 5 | 1021 | 104 | 25150 | 0.62 | 0.00 | 0.00 | 1.2 |
657 | hsa01030 | Glycan structures - biosynthesis 1 - Homo sapiens (human) | 3 | 1023 | 115 | 25139 | 0.63 | 0.00 | 0.00 | 0.6 |
658 | 72766 | Translation | 7 | 1019 | 155 | 25099 | 0.68 | 0.01 | 0.01 | 1.1 |
659 | hsa00510 | N-Glycan biosynthesis - Homo sapiens (human) | 2 | 1024 | 41 | 25213 | 0.68 | 0.00 | 0.00 | 1.2 |
660 | 168254 | Influenza Infection | 5 | 1021 | 164 | 25090 | 0.69 | 0.00 | 0.01 | 0.8 |
661 | hsa04742 | Taste transduction - Homo sapiens (human) | 1 | 1025 | 53 | 25201 | 0.72 | 0.00 | 0.00 | 0.5 |
662 | 157579 | Telomere Maintenance | 3 | 1023 | 68 | 25186 | 0.76 | 0.00 | 0.00 | 1.1 |
663 | 72163 | mRNA Splicing - Major Pathway | 2 | 1024 | 85 | 25169 | 0.78 | 0.00 | 0.00 | 0.6 |
664 | 72172 | mRNA Splicing | 2 | 1024 | 85 | 25169 | 0.78 | 0.00 | 0.00 | 0.6 |
665 | 162587 | HIV Life Cycle | 4 | 1022 | 88 | 25166 | 0.78 | 0.00 | 0.00 | 1.1 |
666 | hsa00240 | Pyrimidine metabolism - Homo sapiens (human) | 4 | 1022 | 90 | 25164 | 0.79 | 0.00 | 0.00 | 1.1 |
667 | 72689 | Formation of a pool of free 40S subunits | 4 | 1022 | 92 | 25162 | 0.79 | 0.00 | 0.00 | 1.1 |
668 | 112295 | Elongation and Processing of Capped Transcripts | 3 | 1023 | 108 | 25146 | 0.80 | 0.00 | 0.00 | 0.7 |
669 | 76043 | Elongation of Intron-Containing Transcripts and co-transcriptional mRNA splicing | 3 | 1023 | 108 | 25146 | 0.80 | 0.00 | 0.00 | 0.7 |
670 | 74160 | Gene Expression | 13 | 1013 | 352 | 24902 | 0.89 | 0.01 | 0.01 | 0.9 |
671 | 74159 | Transcription | 6 | 1020 | 155 | 25099 | 1.00 | 0.01 | 0.01 | 1.0 |
672 | 195721 | Signaling by Wnt | 2 | 1024 | 58 | 25196 | 1.00 | 0.00 | 0.00 | 0.8 |
673 | 109970 | Global Genomic NER (GG-NER) | 1 | 1025 | 30 | 25224 | 1.00 | 0.00 | 0.00 | 0.8 |
674 | 168273 | Influenza Viral RNA Transcription and Replication | 1 | 1025 | 36 | 25218 | 1.00 | 0.00 | 0.00 | 0.7 |
675 | 168255 | Influenza Life Cycle | 1 | 1025 | 40 | 25214 | 1.00 | 0.00 | 0.00 | 0.6 |
676 | 112386 | Pausing and recovery of elongation | 1 | 1025 | 27 | 25227 | 1.00 | 0.00 | 0.00 | 0.9 |
677 | 167172 | Transcription of the HIV genome | 1 | 1025 | 46 | 25208 | 1.00 | 0.00 | 0.00 | 0.5 |
678 | 167200 | Formation of HIV-1 elongation complex containing HIV-1 Tat | 1 | 1025 | 24 | 25230 | 1.00 | 0.00 | 0.00 | 1.0 |
679 | hsa00512 | O-Glycan biosynthesis - Homo sapiens (human) | 1 | 1025 | 30 | 25224 | 1.00 | 0.00 | 0.00 | 0.8 |
680 | 72187 | mRNA 3'-end processing | 1 | 1025 | 28 | 25226 | 1.00 | 0.00 | 0.00 | 0.9 |
681 | 112296 | Post-Elongation Processing of Intron-Containing pre-mRNA | 1 | 1025 | 28 | 25226 | 1.00 | 0.00 | 0.00 | 0.9 |
682 | 168325 | Viral Messenger RNA Synthesis | 1 | 1025 | 36 | 25218 | 1.00 | 0.00 | 0.00 | 0.7 |
683 | 75955 | RNA Polymerase II Transcription Elongation | 1 | 1025 | 37 | 25217 | 1.00 | 0.00 | 0.00 | 0.7 |
684 | 113418 | Formation of the Early Elongation Complex | 1 | 1025 | 28 | 25226 | 1.00 | 0.00 | 0.00 | 0.9 |
685 | 167169 | HIV-1 Transcription Elongation | 1 | 1025 | 30 | 25224 | 1.00 | 0.00 | 0.00 | 0.8 |
686 | 109688 | Cleavage of Growing Transcript in the Termination Region | 1 | 1025 | 39 | 25215 | 1.00 | 0.00 | 0.00 | 0.6 |
687 | 112382 | Formation of RNA Pol II elongation complex | 1 | 1025 | 37 | 25217 | 1.00 | 0.00 | 0.00 | 0.7 |
688 | 76044 | Post-Elongation Processing of the Transcript | 1 | 1025 | 39 | 25215 | 1.00 | 0.00 | 0.00 | 0.6 |
689 | 73856 | RNA Polymerase II Transcription Termination | 1 | 1025 | 39 | 25215 | 1.00 | 0.00 | 0.00 | 0.6 |
690 | 72202 | Transport of Mature Transcript to Cytoplasm | 1 | 1025 | 26 | 25228 | 1.00 | 0.00 | 0.00 | 0.9 |
691 | 112387 | Elongation arrest and recovery | 1 | 1025 | 27 | 25227 | 1.00 | 0.00 | 0.00 | 0.9 |
692 | 73937 | Transcription-coupled NER (TC-NER) | 1 | 1025 | 41 | 25213 | 1.00 | 0.00 | 0.00 | 0.6 |
693 | 73885 | Nucleotide Excision Repair | 1 | 1025 | 45 | 25209 | 1.00 | 0.00 | 0.00 | 0.5 |